NIA AA Revised Clinical Criteria AAIC 2023

Website for feedback: alz.
org/nia-aa
DRAFT as of JULY 15, 2023 For Public Comment @ AAIC23
1 NIA-AA Revised Clinical Criteria for Alzheimer's Disease

2
3 Abstract
4 The National Institute on Aging and the Alzheimer’s Association (NIA-AA) convened 3
5 separate work groups in 2011 and a single work group in 2018 to create recommendations for the
6 diagnosis and characterization of Alzheimer’s disease (AD). The NIA-AA also convened a
7 workgroup that published a consensus document on the neuropathologic diagnosis of AD in
8 2012. Several core principles emerged from these efforts which we regard as fundamental
9 tenants. These include, Alzheimer’s disease (AD) should be defined biologically, not based on a
10 clinical syndrome(s). The disease is a continuum that is first evident with the appearance of brain
11 pathologic changes in asymptomatic individuals and progresses through stages of increasing
12 pathologic burden eventually leading to the appearance and progression of clinical symptoms.
13 Pathophysiologic mechanisms involved with aggregation and clearance of protein fragments may
14 be involved very early in the disease process, but these are not yet well understood. The disease
15 is diagnosed in vivo by abnormalities on core biomarkers. In the 2018 document, biomarkers
16 were categorized based on the pathogenic processes measured using a classification scheme
17 labeled AT(N). Eight different AT(N) profiles were identified, and individuals were staged based
18 on integrating biomarker profile and the severity of the clinical impairment.
19 This document updates the 2018 research framework document in response to several recent
20 developments. First, no disease targeted therapies had received regulatory approval in 2018 but
21 since then several have. In response, the present document has progressed from a framework for
22 research, to criteria for diagnosis and staging that are intended for clinical use as well as
23 research. Second, validated biomarkers in 2018 were based on either CSF assays or imaging.
24 Since then, plasma-based biomarkers with excellent diagnostic performance have been
25 developed and clinically validated. The present document has correspondingly incorporated
26 plasma biomarkers into updated criteria for biomarker categorization, disease diagnosis and
27 staging. Third, research studies have demonstrated that imaging and fluid biomarkers within a
28 category are not equivalent for many use cases. In the present document we have updated
29 biomarker classification criteria to accommodate nonequivalence between fluid and imaging
30 biomarkers within a category.
Page 1 of 39
31 Defining neurodegenerative diseases biologically, rather than based on syndromic

32 presentation, has become a unifying concept common to all neurodegenerative diseases, not just
33 AD, and the present document is consistent with this overarching theme.
34
35
36 1) Background
37 In 2011 the National Institute on Aging and the Alzheimer’s Association (NIA-AA)
38 convened three workgroups that published separate recommendations for the diagnosis and
39 evaluation of Alzheimer’s disease in its preclinical, mild cognitive impairment, and dementia
40 phases 1-3. In 2012 an NIA-AA workgroup published a consensus document on the
41 neuropathologic diagnosis of AD 4,5. Several years later, the NIA-AA convened a single
42 workgroup to update 2011 recommendations for diagnosis and staging. The product of that
43 workgroup, published in 2018, was labeled a research framework 6. The 2018 publication stated
44 that the framework should be updated in the future but did not specify a rigid schedule; rather,
45 updates should occur as needed in response to scientific advances. Major developments have
46 occurred since 2018 which now warrant an update.
47 The convening organization for this update is the Alzheimer’s Association. The
48 Alzheimer’s Association identified a 4-person core leadership group for this effort (i.e., a
49 steering committee) as well as a larger full workgroup. Members of the full workgroup were
50 selected to provide a range of relevant scientific expertise, to achieve a representative sample of
51 professional stakeholders, a balance of academic and industry representation, sex/ethnicity, and
52 geographic location. The steering committee also engaged expert advisors to provide reviews of
53 the project.
54
55 1.1) Modular updates
56 We designate this work as a modular update to the 2011 and 2018 versions of the NIA
57 AA documents. The term modular update reflects the idea that periodic publications updating
58 those aspects of the NIA AA criteria that are no longer current due to advances in the field are
59 needed; but we leave intact core principles developed in the earlier documents that remain valid
Page 2 of 39
60 (text box 1). The advantage of modular updates is that those aspects that need to be updated will
61 be addressed without having to recapitulate the entire AD criteria every few years.
62
63 1.2) Motivation for the modules that are updated
64 Developments that prompted this update include the following (text box 2). Disease
65 targeted treatments for AD have for the first time received regulatory approval. The prospect of
66 targeted therapies entering clinical practice makes conceptual alignment between industry,
67 academia and clinicians around biomarker classification, AD diagnosis, and biologically based
68 staging of AD highly relevant. A major new direction therefore is to expand the 2018 framework
69 from a research-only focus to one that provides recommendations that are applicable for both
70 research and clinical care. The title of this modular update, NIA-AA Revised Clinical Criteria for
71 Alzheimer's Disease, reflects this progression in focus.
72 The most significant advance in AD diagnostics in recent years has been the development
73 of plasma biomarkers with excellent diagnostic performance. This now makes biological
74 diagnosis of AD (which previously required PET or CSF assays) generally accessible and is
75 projected to revolutionize research and clinical care.
76 An important product of recent research is the recognition that imaging and fluid
77 biomarkers within a pathobiological AT(N) category are not interchangeable for many use cases.
78 The present document is updated to reflect this.
79 This updated criteria document was constructed with the intent that it would be useful for
80 academia, industry, and clinical practice. The specific objectives of this work were to provide
81 updates addressing the categorization of biomarkers, the biologically-based diagnosis of AD, the
82 biological staging of AD, integrated biological and clinical staging, and multimodality biomarker
83 profile characterization to identify co- pathologies.
84
85
86 2) Biomarker categorization
87 Categorization of biomarkers as defined here refers to grouping biomarkers into

88 categories that reflect a common proteinopathy or pathogenic process. In contrast, disease
Page 3 of 39
89 staging, which is addressed later, is based on the timing/onset of biomarker abnormalities in the
90 natural history of the disease. Categorization of biomarkers in the 2018 framework assumed
91 equivalence of fluid and imaging biomarkers within each AT(N) category. Ample evidence has
92 accumulated that this is often not the case, therefore in this update we explicitly break away from
93 the assumption of equivalence between imaging and fluid biomarkers within a given category.
94 Imaging biomarkers measure cumulative effects and map onto established neuropathologic
95 constructs 7-13. Fluid biomarkers represent net of rates of production/clearance of analytes in near
96 real time.
97 We group biomarkers into 3 broad categories: core AD biomarkers, non-specific
98 biomarkers that are important in AD pathogenesis but are also involved in other
99 neurodegenerative diseases, and biomarkers of common non-AD co-pathologies (Table 1).
100 Within each of these 3 broad categories we further subcategorize biomarkers by the specific
101 proteinopathy or pathogenic process that each measures. Within each biomarker subcategory we
102 list fluid and imaging biomarkers in separate columns to highlight the distinction. The 2018
103 framework recognized the need to modify the AT(N) biomarker classification scheme to
104 incorporate newly developed biomarkers within an existing AT(N) category which we have done
105 by including recently developed plasma biomarkers of A, T and (N) in this update. The 2018
106 framework also called for incorporating new biomarker categories beyond AT(N) as appropriate.
107 This was denoted as ATX(N) where X indicated a new biomarker category beyond A, T or (N).
108 Accordingly, Tables 1-3 have 3 new biomarker categories: I for inflammatory/immune
109 mechanisms, along with categories for two common non-AD co-pathologies - vascular brain
110 injury (V) and synucleinopathy (S).
111 Use cases for biomarkers fall into several categories: diagnosis; staging and prognosis;
112 multi modal biomarker characterization of individuals to aid in identification of co-pathologies;
113 and, indicators of biological treatment effects. These topics are addressed in subsequent sections
114 but use cases for specific biomarker categories are outlined in Table 2. Tables 1 and 2 are
115 limited to biomarkers currently suitable for clinical use. Biomarkers that are currently suitable
116 for research use appear in Table 3. Biomarkers were placed into Tables 1,2 vs Table 3 based on
117 the committee’s assessment of the strength of available evidence of high diagnostic accuracy
118 (sensitivity, specificity) compared to a valid gold standard, high reproducibility, and diagnostic
119 utility based on clinical studies in real world settings 14,15.
Page 4 of 39
120
121 2.1) Core AD biomarkers
122 Core AD biomarkers are those in the A and T categories. A and T biomarkers map onto
123 the two proteinopathies that define AD and can therefore be used to diagnose the disease. While
124 fluid and imaging biomarkers within an A or T subcategory represent distinct biochemical pools
125 of a given protein, they reflect the same pathogenic process of protein accumulation 16. For
126 example, the A category denotes biomarkers of the β-amyloid proteinopathy pathway.
127 Nevertheless, abnormal fluid A biomarkers specifically indicate dysregulated Aβ metabolism
128 and processing, while imaging (amyloid PET) denotes aggregated Aβ in β-amyloid plaques.
129 Fluid biomarkers detect soluble Aβ peptides which are the molecular building blocks of what can
130 become insoluble β-amyloid aggregates in plaques. Similarly, the T category denotes biomarkers
131 of AD tau proteinopathy. Abnormal fluid T biomarkers denote dysregulated tau metabolism and
132 processing, while imaging (tau PET) denotes aggregated pathologic tau deposits. While soluble
133 phosphorylated N terminal tau fragments may not aggregate into neuritic threads and
134 neurofibrillary tangles themselves, mid-region fragments that contain the micro tubule binding
135 domain do. And, all fragments are derived from the same parent tau protein.
136 Fluid ptau becomes abnormal well before tau PET and the two T measures thus are often
137 discordant in the early or mid-portions of disease evolution 17-20. In contrast, while fluid Aβ42/40
138 may become abnormal slightly before amyloid PET, the discrepancy in timing is not as apparent
139 as between fluid ptau and tau PET 18,19,21-23. The discordance in timing of fluid ptau vs tau PET
140 has invited much speculation. Tau phosphorylation (and other post translational modifications)
141 and secretion may represent a neuronal response to β-amyloid plaques 24.
142 Plasma and CSF Aβ42/40 both correlate with amyloid PET and predict clinical
143 progression: however, the fold difference between individuals with vs without β-amyloid
144 pathologic change is around 50% for CSF Aβ42/40 but 10%-15% for plasma Aβ42/40 25-28.
145 Plasma and CSF assays for ptau at several different phosphorylation sites discriminate AD from
146 non-AD clinical phenotypes, predict future clinical change and correlate with amyloid PET, tau
147 PET and post-mortem measures of AD neuropathologic change 19,29-38. Head-to-head
148 comparisons of various plasma assay platforms for both Aβ42/40 and ptau show considerable
149 variation in diagnostic performance 39-42. Similarly, a variety of ligands exist for amyloid PET
Page 5 of 39
150 and tau PET, and several have been approved by the FDA. Readers are referred to recent reviews
151 for details describing specific fluid biomarker assays and PET ligands 14,39,43.
152 Two CSF assays for β-amyloid have FDA and IVDR-CE approval for clinical use. Many
153 current plasma assays for both Aβ and tau are listed as suitable for research use (Table 3). Some
154 of these may advance to general clinical use, but at this point that is difficult to determine and
155 will ultimately depend on utility assessments by users. Under the category of “A” fluid assays in
156 Table 3 we list Aβ oligomers with the intent to include assays to detect both globular oligomers
157 and linear protofibrils. Both are soluble but have different quaternary structures and
158 characteristics and for that reason the term oligomers is not consistently applied to both.
159
160 2.2) Biomarkers that are non-specific but important in AD pathogenesis
161 In this update we identify two categories of biomarkers that are not specific to AD but are
162 important in the AD pathogenic pathway. These are N and I biomarkers.
163 In the 2018 research framework we placed (N) in parenthesis to emphasize that, in
164 contrast to A and T, (N) biomarkers were not specific for AD. From this point forward we no
165 longer employ this notation because it should be clear from the construction of the present
166 document that N biomarkers do not belong in the same group as core biomarkers. N biomarkers
167 denote evidence of past or active neuronal injury or neurodegeneration. While neurodegeneration
168 and neuronal injury are obviously important steps in AD pathogenesis, abnormalities in N
169 biomarkers occur in many other conditions including non-AD neurodegenerative diseases,
170 traumatic brain injury, and ischemic injury. Fluid N biomarkers denote active neuronal injury or
171 more subtle neuronal dysfunction. Neurogranin is a marker of post-synaptic injury and
172 degeneration while SNAP- 25 and GAP-43 are markers of pre-synaptic degeneration and
173 dysfunction 14,39,43. NfL is a marker of large caliber axonal injury that can be measured in CSF
174 or plasma and is used clinically in various disorders including MS, ALS, and traumatic brain
175 injury 14,43-52. The absence of total tau from the fluid biomarker N category in Tables 1-3 is a
176 departure from the 2018 research framework. CSF and plasma total tau begin to increase early in
177 the disease course in autosomal dominant AD 18 and closely correlate with fluid ptau in
178 autosomal dominant and sporadic AD 53. This could be taken as evidence that total tau should be
179 considered a T biomarker. However, CSF and plasma total tau also increase dramatically in
180 Creutzfeldt Jacob disease, head trauma, anoxia, cerebral infarction, as well as peripheral
Page 6 of 39
181 neuropathies which has been taken as evidence that this belongs in the N category 53,54. When all
182 evidence is considered, it is unclear how best to categorize this measure.
183 Imaging N biomarkers represent the net result of cumulative insults to the neuropil.
184 Neurodegenerative loss of neurons and synapses results in volume loss (or decreased cortical
185 thickness) on MR 55,56 and FDG hypometabolism. Like their fluid counterparts, imaging N
186 biomarkers are not specific to AD and may result from a variety of prior or ongoing brain insults
57,58
187 . Diffusion and perfusion MR are complicated and are discussed in the V section below. PET
188 imaging of synapses has recently entered the research arena based on ligands that bind to the
189 synaptic vesicle glycoprotein 2A, a presynaptic component that may be lost with
190 neurodegeneration 59. Initial studies employed the [11C]-labeled compound UCB-J that
191 demonstrated reduced synaptic density in cortex of AD patients 60,61; subsequent studies have
192 indicated the feasibility of this approach using an [18F]-labeled ligand, SynVesT-1 62. How this
193 family of radiopharmaceuticals will be used in research and whether they will be useful in
194 clinical application is unknown at this time.
195 In the paragraphs above we list both fluid and imaging biomarkers of synaptic function in
196 the N biomarker category. Synaptic loss and dysfunction are an important feature of
197 neurodegenerative diseases, most notably AD. A future direction for the field could be to identify
198 more specific roles that various synaptic biomarkers could play in defined contexts of use. It
199 could be beneficial to break out synaptic biomarkers from the broader N category in the future.
200 EEG may be one of the synaptic measures since it provides insight into synaptic connectivity.
201 Functional connectivity measures have shown to be related both to cognitive performance and to
202 AD pathophysiology63.
203 Biomarkers of inflammatory/immune processes (I) are divided into 2 subcategories,
204 activation of astrocytes and microglia. A substantial body of evidence from genetics, animal
205 models, and neuropathology indicates that immune/inflammatory mechanisms are important in
206 AD pathogenesis 64-66. And a growing list of interventional strategies targets
207 immune/inflammatory pathways 67. Glial fibrillary acidic protein (GFAP) can be measured in
208 plasma or CSF and is a marker of astrocytic activation. It is not specific to AD but is associated
209 with higher risk of incident dementia and faster rates of cognitive decline 14,39,50,52,68-72. Soluble
210 TREM2 is a biomarker of microglial activation that can be measured in CSF. Longitudinal
211 studies indicate that sTREM2 begins to increase in the preclinical phase of the disease process
Page 7 of 39
212 around the time of A biomarkers but decreases at later AD stages 73,74. Cytokines and
213 complement factors may be CSF biomarkers of both astrocytic and microglial activation. PET
214 ligands exist for microglia and astrocytic activation. This is an active area of research but none of
215 these ligands are thought to be suitable for clinical use currently.
216
217 2.3) Biomarkers of common non-AD co-pathologies
218 We list biomarkers of α-synuclein (S) and vascular brain injury (V) in Tables 1-3 under
219 the heading of biomarkers of common non-AD co-pathologies. α-synuclein seed amplification
220 assays (αSyn-SAA) in CSF have gained attention as diagnostic biomarkers in patients with
221 Parkinson’s disease (PD) and Dementia with Lewy Bodies (DLB), recently relabeled as
222 Neuronal Synuclein Diseases 75,76. αSyn-SAA are sensitive and specific for antemortem
223 identification of limbic/neocortical α-synuclein pathologic change (but not for amygdala
224 predominate Lewy body disease (LBD)) in patients with limbic/neocortical α-synuclein as a
225 primary or as a co-pathology 77. These assays are less sensitive to α-synuclein inclusions in multi
226 system atrophy where the cellular location and conformation of inclusions differ from DLB and
227 PD 78,79. αSyn-SAA currently yield a binary positive/negative (or inconclusive) output that is not
228 quantitative 80. Utility of these assays in peripheral tissue biopsy samples is being studied and is
229 listed in Table 3 for research use 81,82. Development of PET ligands for α synuclein is an active
230 area of research but at present, no ligands are currently available for the detection of a-synuclein
231 co-pathology in patients with AD 83,84. DAT SPECT is a dopamine transporter imaging method
232 that is used clinically to assess loss of striatal dopaminergic neurons in the evaluation of patients
233 with movement disorders or suspected LBD 85,86. DAT scan is not listed in Tables 1-3 because it
234 is not a direct measure of α synuclein pathologic change but rather is an indicator of striato-
235 nigral degeneration.
236 Cerebro vascular disease is an umbrella term that encompasses different forms of
237 vascular brain injury (V). Several different modalities or imaging findings are listed in the V
238 category in Tables 1-3. At this point, however, a single summary measure composed of different
239 imaging findings has not been widely accepted. Macroscopic cerebral infarctions, including both
240 large cortical and subcortical (lacunar) infarctions, on anatomic MR are the most definitive
241 biomarker of ischemic vascular brain injury and are widely employed for this purpose in clinical
242 care (Tables 1,2). Microinfarctions are an important neuropathologic substrate of cognitive
Page 8 of 39
243 impairment 87-89. Most lie beneath the spatial resolution of clinical MRI 90; however, a subset of
244 cortical microinfarctions may be detected even on clinical grade MRI with modern methods 91.
245 MR methods that may be useful indicators of small vessel disease include CO2 reactivity 92and
246 the presence of abundant dilated perivascular spaces 93. State of the art methods in neuroimaging
247 of small vessel disease are reviewed in the recent STRIVE-2 guidelines 94. Diffusion weighted
248 imaging is used routinely in clinical practise to identify cytotoxic edema due to acute cerebral
249 infarction. Quantitative diffusion MR has gained traction as a method to detect loss of
250 microscopic tissue integrity due to small vessel disease 95-98. But, diffusion MR (a broad field
251 that encompasses many different approaches) is also abnormal in neurodegenerative diseases,
252 traumatic brain injury etc. The same reasoning applies to perfusion MR (arterial spin labeling or
253 variants). Because quantitative diffusion MR and perfusion MR both reflect physiological
254 responses to brain injury that may result from multiple etiologies they are listed in Table 3 as
255 indicators of both V and N. White matter hyperintensities on MR have long been interpreted to
256 indicate microvascular ischemic injury 58 and are commonly used in clinical practise for this
257 purpose. However, WMH may also be attributed to Wallerian degeneration, autoimmune
258 demyelination, loss of blood brain barrier integrity from cerebral amyloid angiopathy, etc.
259 Collection of PET data immediately following injection contains information about cerebral
260 perfusion that may also be useful as a measure of vascular physiology or neurodegeneration
99,100
261 . There are no specific fluid vascular injury biomarkers that are suitable for clinical use but
262 we list CSF sPDGFRβ (an indicator of pericyte injury) as a fluid V biomarker for research use
101
263 .
264 The vascular markers described above are linked with traditional systemic vascular risk
265 factors and cerebral ischemia. Cerebral amyloid angiopathy (CAA) merits special menton
266 because while the disorder is one of cerebral vessels, the etiology is disordered processing of Aβ
267 rather than traditional systemic vascular risk factors and CAA is commonly observed in
268 association with Aβ plaques in AD. CAA represents the aggregation of Aβ in cerebral vessel
269 walls, replacing or damaging the media, leading to vessel fragility 102. This in turn can lead to
270 spontaneous leakage or exudate of intravascular contents, including heme products, into brain
271 parenchyma or the sulcal space. The result is seen on MR as superficial siderosis or cerebral
272 micro bleeds, typically in a lobar distribution which may distinguish CAA-related microbleeds
273 from those associated with chronic hypertension more often found in the sub-cortical regions and
Page 9 of 39
274 brainstem 103. Rarely, spontaneous vasogenic edema can be seen. A serious potential
275 complication is lobar hemorrhage.
276 TDP-43 or LATE is a clinically important and common late life co-pathology but is not
277 listed in Tables 1-3 because no confirmed biomarkers exist at this time 104. Biomarkers of 4R
278 tauopathy would also be useful. While some PET ligands may bind to 4R tau aggregates, none
279 have gained wide use clinically or in research because they are unable to identify individual
280 patients with 4R tauopathy 105-107. CSF dynamics disorders may also contribute to impairment
281 and can be detected by MRI 108.
282
283 3) Diagnosis
284 In this update we propose that AD can be diagnosed by the presence of any abnormal
285 core AD biomarker – i.e., fluid Aβ42/40, ptau, amyloid PET, or neocortical tau PET (text box
286 3). Medial temporal lobe tau PET uptake without amyloidosis is considered primary age related
287 tauopathy (PART) 109. PART has been controversial and is not considered to represent AD in the
288 NIA AA guidelines for neuropathologic assessment of AD 4,5. Natural history studies have
289 unequivocally shown that AD biomarkers become abnormal long before symptoms arise. Our
290 rational for diagnosing AD by the presence of any abnormal core biomarker is that the disease
291 exists when the earliest manifestation of AD pathophysiology can be detected by biomarkers,
292 even though onset of symptoms may be years in the future. An analogy can be drawn with adult-
293 onset diabetes, where most individuals are diagnosed by screening HbA1C or fasting glucose
294 testing while they are asymptomatic. Symptoms from adult-onset diabetes may not appear for
295 years after initial diagnosis, but the disease exists at this initial stage and is routinely diagnosed
296 while patients are asymptomatic. This biological definition of AD is consistent with the
297 distinction between a disease vs illness. A disease is a pathobiological condition that will
298 ultimately manifest with symptoms if an affected individual survives long enough. In contrast the
299 term illness denotes signs and symptoms that result from the disease. Importantly, defining a
300 disease by its biology rather than syndromic description is becoming a unifying concept common
301 to all neurodegenerative diseases as exemplified by recent efforts in Parkinson’s disease 110-112
302 Huntington’s disease 113, and amyotrophic lateral sclerosis 114.
Page 10 of 39
303 In the 2018 research framework, an A+T+ biomarker profile was required for a
304 designation of Alzheimer’s disease based on the AT(N) biomarker classification scheme. A+T-
305 individuals were described as having Alzheimer’s pathologic change. A+T+ corresponds to what
306 neuropathologically would be intermediate/severe AD neuropathologic change and thus the in
307 vivo definition of AD aligned with the established neuropathological definition 4,5. By defining
308 AD as any abnormal core AD biomarker, as we have done in this update, the link between the
309 pathologic gold standard and the in vivo definition will not always be consistent. Many
310 individuals with only an abnormal amyloid PET, fluid Aβ 42/40 or ptau may not be at Braak
311 NFT stage 3 or higher neuropathologically and thus would not qualify for a pathological
312 diagnosis of intermediate/high AD neuropathologic change.
313
314 3.1) Limitations of currently available biomarkers
315 Important considerations in diagnosing AD biologically are the limitations of currently
316 available biomarkers (text box 4). First, PET and fluid biomarkers are less sensitive than
317 neuropathology. The FDA-approved PET amyloid and tau agents are incapable of accurately
318 identifying low densities and/or distributions of AD pathologic change restricted to medial
319 temporal structures. The FDA approved amyloid PET tracers cannot, by visual reads, reliably
320 detect sparse neuritic plaques 7-9,115,116 and tau PET cannot reliably differentiate between
321 neuropathologically defined Braak stages I-III 12,13,117. Newer plasma ptau assays are effective in
322 identifying neuropathologically defined Alzheimer’s disease at intermediate and high pathologic
323 change levels but do not reliably discriminate among Braak stages I-IV in cognitively
324 unimpaired subjects 118.
325 Second, there has been insufficient validation of biomarkers against a rigorous
326 neuropathologic standard in some areas. Generally, only the FDA-approved PET amyloid and
327 tau ligands have had sufficient validation against autopsy 9,13,115,116. Biofluid assays do not
328 require FDA approval; the much-less rigorous CLIA or CAP (in the US) certifications do not
329 require autopsy validation.
330 Third, biomarkers are not available for all relevant neuropathologies, therefore it cannot
331 be known with certainty in vivo what neuropathologies in addition to AD are present in any
332 individual, or what the proportional neuropathologic burden is among various pathologies.
Page 11 of 39
333 Finally, the proportion of the observed cognitive deficit in any individual that is
334 attributable to AD vs other neuropathologies cannot be known with certainty given the present
335 state of technology (text box 4).
336
337 3.2) Thresholds
338 The limitations of biomarkers discussed above are all relevant; however, diagnostic
339 performance of a biomarker and its relationship to a neuropathologic standard will always
340 depend on the normal/abnormal cutpoints selected. Sensitivity and specificity are obviously
341 inversely related and optimizing one vs the other will depend on the desired context of use.
342 Selecting cutpoints is an active research area and changes to what now might be considered
343 appropriate are likely to occur. For example, what might be considered an appropriate amyloid
344 PET cutpoint of Centiloid 20-25 8 could be too conservative for use cases that require early
345 detection 119-121. Lowering the cutpoint would obviously increase sensitivity but at the expense of
346 specificity.
347
348 3.3) Protections from misdiagnosis
349 Diagnosing AD by an abnormal core biomarker demands a high level of fidelity when
350 applied clinically. However, any diagnostic test value, fluid or imaging, has a degree of
351 uncertainty associated with it. We therefore recommend 3 protections against misdiagnoses (text
352 box 3). First, we recommend using only fluid assays or PET ligands for clinical diagnosis and
353 staging/prognosis that have met rigorous validation standards. Second, we recommend
354 conservative interpretation of values near cutpoints and we recommend employing an
355 indeterminant zone around a normal/abnormal biomarker cutpoint. Third, biomarker results
356 should always be interpreted in the context of an individual patient’s history.
357
358 3.3.1) Rigorous validation
359 We recommend using only assays/tests for clinical diagnosis and staging/prognosis that
360 have met rigorous validation standards. For both PET and fluid assays this would include
361 validation against an accepted gold standard. Ideally the standard would be large biomarker to
362 autopsy correlation studies, but this may not always be possible given the challenges with
363 obtaining biomarker and autopsy sampling close in time in representative samples. We avoid
Page 12 of 39
364 prescribing specific performance metrics; however, fluid or PET biomarkers used for diagnosis
365 should meet high standards for sensitivity, specificity, and precision. An important feature of
366 validation is evidence of diagnostic utility from prospective clinical studies in real world settings
367 as opposed to assessment limited to highly selected cohorts 14,15,122-125. Plasma AD biomarker
368 assays have only recently reached sufficient accuracy for clinical use and this field is still in a
369 period of active development. Head-to-head comparisons of different plasma Ab 41 and ptau 40
370 assays have shown wide variability in diagnostic performance. Clinical use of plasma biomarkers
371 should therefore be undertaken with particular attention to rigorous performance validation.
372
373 3.3.2) Conservative interpretation of values near a cutpoint; the intermediate zone
374 Except for αSyn-SAA, all biomarkers we discuss exist on a continuous scale and the
375 definition of an abnormal test value requires creating a cut point in that continuous range.
376 Cutpoints denoting normal vs abnormal values may be selected by various means 126 and will
377 vary with the assay platform, and for PET will depend on the specific ligand and details of the
378 analytic pipeline. However, regardless of assay or modality, a level of diagnostic uncertainty
379 exists for values at or near any cutpoint. When using a fluid or PET biomarker quantitatively for
380 diagnosis, our recommendation therefore is to report study results with 3 elements: first, what is
381 the value on a continuous scale (with an appropriate reference scale); second, is the value normal
382 or abnormal on the basis of an established cut point; third, where does this value fall with respect
383 to a zone of uncertainty on either side of the normal/abnormal cut point. The zone of uncertainty
384 thus divides the continuous range of values into confidently normal, confidently abnormal, and
385 indeterminant. In addition, incorporating a zone of uncertainty may lessen fluid/ PET
386 discordances, particularly for A biomarkers.
387 For imaging, visual reads would provide a normal/abnormal output. In addition, the
388 approach of labeling some exams indeterminate is common in clinical radiology and serves the
389 same function as the zone of uncertainty in quantitative analyses. However, quantitative analysis
390 of PET is more sensitive than visual interpretation and, for example, can detect nominally
391 negative but increasing levels of Aβ pathologic change that are likely to be clinically meaningful
120,127,128
392 . For this reason, the committee recommends greater incorporation of quantitative
393 analysis in both research and clinical use.
394
Page 13 of 39
395 3.3.3) Clinical context

396 No biomarker test should be ordered or interpreted in the absence of clinical context. For
397 example, head trauma or cardiorespiratory arrest may acutely and transiently increase ptau
398 values 53. Some MAPT mutation carriers with a 3R+4R tauopathy may have elevated ptau 217 in
399 the absence of amyloid pathologic change 129. Elevated ptau 181 has been reported in autopsy
400 verified ALS cases with little to no AD copathology 130. Certain medications and impaired renal
401 function can elevate, while obesity may depress, some plasma biomarker values 131,132. All these
402 potentially confounding situations should be obvious clinically. Knowledge of patient history is
403 necessary to avoid interpretation errors.
404
405
406 3.4) Use cases
407 While a purely symptomatic therapy may not require documentation of AD biology,
408 therapy directed toward a biological target requires confirmation of that biology. The major use
409 case for the biological diagnosis of AD in clinical trials is as an inclusion criterion. Use cases for
410 biological diagnosis of AD in clinical care include counseling, tailoring medications for
411 symptomatic (i.e., non-disease modifying) treatment, and determining eligibility for disease
412 targeted treatment based on drug registration criteria 133. Specific use cases will determine how
413 biomarkers are employed. In many instances a single biomarker will be sufficient for clinical
414 diagnosis and trial inclusion, for example a single biomarker documenting the presence of β-
415 amyloid plaques is sufficient for inclusion in trials or for instituting clinical treatment directed
416 against fibrillar β-amyloid. In the next section we discuss staging which would require multiple
417 biomarkers.
418
419
420
421 4) Biological disease staging
422 We distinguish staging the severity of AD biology with biomarkers from staging the
423 severity of clinical symptoms. This section addresses the former. Disease staging is a measure of
424 biological severity which can be used to identify groups of individuals who have similar
Page 14 of 39
425 expected natural history outcomes and should require similar treatment. While diagnosis of AD
426 is based on an abnormal core biomarker study, the prognosis associated with an abnormal test
427 result will not be the same for different biomarkers. The short to medium term prognosis of an
428 individual with abnormality only on an early changing core biomarker will be different from
429 someone with an abnormal later changing core biomarker, yet both individuals will be diagnosed
430 with AD. Biological staging of the disease is therefore an important element of this update.
431 An important principle is that biological staging of AD applies only to individuals in
432 whom the disease has been diagnosed by an abnormal core biomarker. AD staging does not
433 apply to individuals who are not in the AD pathway, and many such individuals exist in
434 observational research cohorts and in the population at large. We have structured this document
435 to reflect this – i.e., diagnosis is the first step and only then does staging of AD become relevant.
436
437 4.1) Approaches to biological staging
438 In the 2018 framework, the “plus/minus” combinations of ATN were used as an informal
439 staging scheme; individuals in the AD continuum were expected to progress from A+T-N- to
440 A+T+N- to A+T+N+. However, in 2018 the term biomarker “profile” was used rather than
441 “staging” to avoid confusion with clinical staging. In this update, however, we recommend an
442 explicit scheme for staging the biological severity of AD that is distinct from staging the severity
443 of clinical impairment.
444 Two general approaches may be taken for biological disease staging. Staging may be
445 based on the order of biomarker events in the natural history of the disease where each event is
446 categorized as present/abnormal (+) or absent/normal (-). This approach assumes that an
447 archetypical order of biomarker events can be established through natural history studies; this
448 sequence of biomarker events is then the de facto staging scheme. Alternatively, biological
449 staging may be based on the magnitude of a continuous biomarker denoting progressively more
450 severe disease. This latter approach is widely used for some diseases (e.g., HgbA1c for diabetes
451 or eGFR for chronic kidney disease) but presents complexity for AD where two defining
452 proteinopathies exist rather than a single physiologic read out.
453
454 4.2) Biological staging
Page 15 of 39
455 We recommend a biological staging scheme that employs only core biomarkers. N
456 biomarkers certainly add prognostic information; an A+T+N+ individual by PET has a worse
457 short-term clinical prognosis that someone who is A+T+N- 134-136. However, the temporal
458 relationships among core biomarkers (A, T) and both N biomarkers and cognitive symptoms are
459 inconsistent between people. Biological staging implies that a person should progress from initial
460 to advanced stages in sequence and N biomarkers do not always follow a stereotypical A+ to T+
461 to N+ sequence. People with amyloidosis, who by definition have AD, may develop significant
462 neurodegeneration prior to tauopathy due to co-pathologies (Figures 1,2). The same reasoning is
463 applicable to I biomarkers. Although inflammation, like neurodegeneration, is obviously an
464 important component of the AD pathological process, we have also not included I biomarkers in
465 the staging scheme. Although, astrocytic activation denoted by elevated GFAP has been
466 proposed as link between β -amyloidosis and tau phosphorylation 137, it has not been
467 unequivocally established where I biomarkers fit into the disease sequence. In addition, like N
468 biomarkers, I biomarkers are involved in non-AD disease processes and therefore the temporal
469 relationships among core biomarkers, I biomarkers and cognitive symptoms will be inconsistent
470 between people with varying types and degrees of non-AD copathology.
471 In keeping with recognition of nonequivalence between imaging and fluid biomarkers we
472 propose separate staging schemes for imaging and fluid but with a common overarching concept.
473 For both imaging and fluid, we describe a 4-stage scheme based on the sequence of events
474 observed in natural history studies: stage a, initial changing biomarkers; stage b, early changing;
475 stage c, intermediate changing; stage d, advanced changing (Table 4, Figure 1). We do not
476 attempt to link PET and fluid biomarker stages but rather describe biological staging separately
477 within each modality.
478 Unlike fluid biomarkers, imaging captures both topographic and magnitude information.
479 Separate staging schemes for amyloid and tau PET have been proposed using either topographic
480 distribution 20,138-145 or cutpoints in the continuous distribution of values from a defined region of
481 interest (ROI) 126,145-147. However, PET staging that integrates both amyloid and tau PET has not
482 been described and a comprehensive disease staging scheme for AD should include both
483 biomarker categories.
484 Highly replicable temporal interrelationships between amyloid PET, tau PET and clinical
485 symptoms exist. This can be summarized as follows. Abnormal amyloid PET often exists as an
Page 16 of 39
486 isolated finding in elderly individuals who are cognitively normal and without neocortical tau
487 PET uptake or neurodegeneration 148-152. In contrast, high levels of neocortical tau are rarely seen
488 in the absence of amyloidosis, are usually accompanied by neurodegeneration and are usually
489 incompatible with normal cognition 151. Clinical symptoms and neurodegeneration are closely
490 related both in time and topographically with tau PET but not amyloid PET 153-155. This set of
491 findings is consistent with a stereotypical sequence of unidirectional biomarker events that can
492 be summarized as: amyloidosis precedes neocortical tauopathy which in turn leads to
493 neurodegeneration and clinical symptoms 152,156-160. Amyloidosis appears to facilitate
494 topographic spread of tauopathy, with the latter most commonly, but not always, beginning in
495 medial temporal areas 20,142.
496 Therefore, for biological staging with PET we propose the following staging scheme
497 (Table 4, Supplementary Table 1): stage a (initial) – abnormal amyloid PET with no uptake on
498 tau PET (A+T-) 127. Stage b (early) – abnormal amyloid PET plus tau PET uptake that is
499 restricted to medial temporal areas (A+TMTL+). Stage c (intermediate) - abnormal amyloid PET
500 plus tau PET uptake in the moderate SUVR range on a neocortical ROI (A+TMOD+). Stage d
501 (advanced) - abnormal amyloid PET plus tau PET uptake in the high SUVR range in the same
502 neocortical ROI (A+THIGH+). Note that this PET staging scheme incorporates 5 elements. Both
503 amyloid PET and tau PET are included to capture the 2 diagnostic proteinopathies. Within tau
504 PET it incorporates staging by both topography (by distinguishing between MTL and neocortical
505 uptake), and by uptake magnitude in the same neocortical meta-ROI. Finally, the neocortical
506 ROI will capture staging for typical but also atypical/hippocampal sparing AD presentations 161.
507 We recognize that amyloid PET, like tau PET, also exists on a continuous scale and that higher
508 amyloid PET SUVR or Centiloid values are associated with more advanced disease and worse
509 outcomes 162-164. However rather than incorporating a separate continuous amyloid PET scale
510 into the PET staging scheme, amyloid PET is denoted in a binary manner with the recognition
511 that increasing amyloid PET Centiloid values do not have widely varying spatial locations and
512 will be captured by progressively worse tau PET stages 164,165.
513 The onset of abnormal ptau 181, 217 and 231 seems to occur around the time of amyloid
514 PET and much earlier than neocortical tau PET abnormalities 18,166. In contrast several more
515 recently developed CSF tau assays (ptau-T205, MTBR-243, and non-phosphorylated tau species)
516 seem more closely linked with the onset of abnormal tau PET and correlate better with tau PET
Page 17 of 39
517 than amyloid PET 166-168. Moreover, a sequence of events has been proposed with these
518 pathologic tau species appearing in the following order: ptau 181, 217 or 231, then ptau- T205,
519 then MTBR-243, then non phosphorylated tau species 166,168. We therefore recommend a staging
520 scheme with fluid biomarkers that follows the same 4-stage approach as described for PET.
521 Stage a (initial) – abnormal Ab 42/40, ptau 217, 231 or 181, and normal ptau-T205, MTBR-243
522 and non-phosphorylated species. Stage b (early) – abnormal Ab 42/40, ptau 217, 231 or 181 and
523 ptau-T205, with normal MTBR-243 and non-phosphorylated species. Stage c (intermediate) –
524 abnormal Ab 42/40, ptau 217, 231 or 181, ptau-T205, and MTBR-243 and normal non-
525 phosphorylated species. Stage d (advanced) – all abnormal (Table 4, Supplementary Table 2).
526 Measurement of ptau-T205 in plasma has recently been reported 166. MTBR-243 and relevant
527 non-phosphorylated species have only been measured in CSF so this staging scheme could not be
528 fully implemented with plasma alone, however plasma assays may become possible for these
529 analytes. Furthermore, the fluid biomarker field is in a period of rapid change and our
530 recommendations for fluid staging should be regarded as conceptual, not as fixed guidelines.
531
532 4.3) Caveats
533 Various assays are available for fluid biomarkers within a category (Table 1-3). Also, a
534 variety of PET ligands exist for both amyloid and tau. We do not specify specific assays, PET
535 ligands or numeric cut points for staging purposes in this document. Nor do we outline a specific
536 triage paradigm for use of different biomarkers in clinical workup or clinical trials. Our position
537 is that researchers and clinicians will make those determinations empirically. Both the
538 quantification of tau PET and fluid biomarker development are in a state of flux and we believe
539 rigid recommendations would not be helpful at this point.
540 We describe separate within-modality staging schemes for imaging and fluid biomarkers
541 but with a common 4-stage framework. It would ideally be possible to link imaging and fluid
542 biomarkers in a single staging scheme that included both; however, this does not seem feasible at
543 present. Standardization of fluid assays and tau PET quantification are currently in flux and
544 cutoffs for various fluid biomarkers, especially plasma, have not yet been established. However,
545 when the field has stabilized, then we envision that quantitative anchors between PET and fluid
546 stages could be operationalized. At present, if both fluid and PET biomarkers are available in an
547 individual, we recommend assigning stage by the method with the most advanced stage.
Page 18 of 39
548 Several caveats are specific to tau PET. First, care must be taken to identify off-target tau
549 ligand binding, which is not relevant to AD staging. For example, uptake may occur in areas of
550 severe neurodegeneration in patients who are in the FTLD spectrum as well as in areas of
551 infarction, but this should be easily recognized as off target based on clinical context. Second, we
552 recognize that medial temporal tauopathy does not always precede neocortical tauopathy 169.
553 However, medial temporal to neocortical spread is by far the most common pattern, and the
554 magnitude of ligand uptake in the neocortical meta-ROI will stage atypical presentations. Third,
555 we employ topographic location of ligand uptake as one element of staging (medial temporal vs
556 neocortical), but we do not specify a rigid set of anatomic ROIs to define the medial temporal or
557 the neocortical meta-ROIs for tau quantitation. Neocortical areas that reflect intermediate and
558 advanced staging by virtue of association with amyloid positivity, diagnostic utility, and
559 prediction of cognitive decline include inferior and lateral temporal and inferior parietal lobes
560 and sampling of these areas should be included in a neocortical tau PET meta ROI 134,136,143,170.
561 Similarly, the medial temporal ROI could include entorhinal cortex, amygdala, and
562 hippocampus. However, off target uptake and binding properties differ among available tau PET
563 ligands and therefore the anatomic extent of medial temporal and neocortical ROIs may need to
564 be tailored to the properties of specific tau PET ligands. Efforts are underway to standardize
565 quantification of tau PET for all tracers (for example, the CenTauR scale 171) in the same way
566 that the Centiloid scale 172 is the standardized method for quantifying amyloid PET. This is an
567 evolving area that will likely undergo changes, and rigid specification of methods at this time
568 seems unwise.
569 The Centiloid scale is the accepted method for quantifying amyloid PET; however, this is
570 based on the anatomic distribution of ligand uptake in sporadic AD 172. Florid striatal amyloid
571 PET uptake often occurs early in individuals with autosomal dominant AD and DSAD which is
572 usually not the case in sporadic AD 173,174. Therefore, the approach to determining A+ vs A- may
573 need special consideration in ADAD and DSAD.
574 We have identified specific fluid biomarkers to denote the early, intermediate, and
575 advanced fluid stages. However, these fluid biomarkers have not yet been widely tested. And,
576 unlike PET where worse biological stage predicts worse clinical prognosis 20,134-136,163,175,176, the
577 prognosis associated with fluid biomarker staging has not been thoroughly established. For this
578 reason, T205, MTBR-243 and other tau species are listed in Table 3 (research use) and not in
Page 19 of 39
579 Tables 1, 2 (clinical use). It is also highly likely that new fluid core biomarkers will be
580 developed.
581 Cut points are obviously needed to operationalize biological staging with biomarkers. In
582 the section on diagnosis, we recommend that all quantitative biomarker reports include an
583 indeterminate zone around a cutpoint – i.e., functionally 3 cutpoints. However, 3 cutpoints
584 around the division between each successive stage is obviously not tenable for staging.
585 Therefore, our recommendation for an indeterminate zone around a diagnostic normal/abnormal
586 cutpoint is applicable to diagnosis but not for staging.
587
588 4.4) Use Cases
589 Disease staging is well established in cancer where staging is used for prognosis, for
590 selecting an optimum treatment, and for creating homogeneous groups for interventional trials.
591 As with other diseases, more advanced biological AD stage predicts worse prognosis (Figure 1)
134-136,163,175,176
592 .
593 Biological staging in clinical trials would sharpen inclusion or stratification criteria by
594 identifying individuals that should respond to treatment in a similar fashion thus decreasing
595 biological heterogeneity and increasing trial efficiency. Inclusion in the Trailblazer-Alz and
596 Trailblazer-Alz 2 studies was based on an abnormal amyloid PET but also on tau PET stage, not
597 a binary normal/abnormal tau PET designation 177. In the A4 and AHEAD studies, while
598 inclusion was based on an abnormal amyloid PET study, study assignment within the trial was
599 based on amyloid PET severity/stage 178,179. In the DIAN-TU NexGen combination (amyloid and
600 tau immunotherapies), the ordering of tau monotherapy followed by the addition of amyloid
601 immunotherapy or amyloid monotherapy followed by the addition of tau immunotherapy is
602 determined by the presence of neocortical tau on PET.
603
604
605 5) Clinical staging
606 5.1) Numeric clinical staging

607 In the 2018 research framework we described a 6-stage numeric clinical staging scheme
608 which is brought forward largely unchanged into this update and readers are referred to the
Page 20 of 39
609 earlier document for additional details. Numeric clinical staging applies only to individuals who
610 are in the AD pathophysiologic continuum and includes the following 6 clinically defined stages
611 (Table 5): 1- biomarker evidence of AD in asymptomatic individuals; 2- transitional decline.
612 These are the earliest detectable clinical symptoms that might be due to AD in individuals who
613 are cognitively unimpaired; 3- objective cognitive impairment but of insufficient severity to
614 result in significant functional loss – i.e., inefficient activities of daily living (ADLs) but still
615 independent; 4- 6 - loss of independence with progressively worse functional loss. Stages 4-6
616 map onto mild, moderate and severe dementia respectively.
617 Numeric clinical stages 1-6 (Table 5) bear a close resemblance to the Global
618 Deterioration Scale 180, with the important distinction that the latter was created before the
619 development of disease specific AD biomarkers. The 6-stage numeric scheme also closely
620 resembles staging in the FDA guidance for conduct of clinical trials in early AD 181.
621 Stage 2 is called out as a distinct transitional stage between asymptomatic (stage 1) and
622 mildly impaired (stage 3) and resembles “stage 3 preclinical AD” in the 2011 NIA AA
623 guidelines 1. This stage is defined by one or more of 3 components: objective cognitive decline,
624 subjective cognitive decline, or subtle neurobehavioral difficulties. All 3 of these components
625 can be attributable to AD but also to factors other than AD, particularly neurobehavioral
626 symptoms (e.g., depression, anxiety, apathy) 182 which are often not associated with
627 neurodegenerative disease. An individual may be placed into stage 2 based on neurobehavioral
628 symptoms alone – i.e., without objective or subjective cognitive decline – but individuals must
629 have cognitive impairment to be placed into numeric stages 3 – 6. Advances in unsupervised,
630 digital cognitive testing may improve the ability to reliably detect the subtle cognitive alterations
631 characteristic of stage 2 through repeated testing, but this remains to be determined.
632 The nature of cognitive decline or impairment in stages 2 - 6 may involve any cognitive
633 domain(s) – not only memory. Clinical staging is based on severity of cognitive/functional
634 impairment rather than on phenotype, but different phenotypic presentations of AD are well
635 known. Five characteristic AD phenotypes are recognized: amnestic or “typical”, language
636 variant, visuospatial variant, behavioral variant and dysexecutive variant which are reviewed in
183,184
637 . Different phenotypes often overlap within an individual and severity of impairment within
638 each domain is variable.
Page 21 of 39
639 Although we describe clinical AD stages, it is important to bear in mind that the severity
640 of clinical impairment is the product of all neuropathological insults an individual has
641 experienced, not only AD. The presence and severity of symptoms in an individual with
642 abnormal AD biomarkers cannot be ascribed solely to AD with confidence particularly in elderly
643 persons because of the likely presence of comorbid pathologic change (Text Box 3 and 5).
644
645 5.2) Stage 0 and genetics
646 The change we propose in clinical staging from 2018 is addition of stage 0. Stage 0
647 represents part of the AD continuum and is defined as an individual with genetically determined
648 AD (which includes autosomal dominant AD (ADAD) or Down Syndrome AD (DSAD, Trisomy
649 21)) 185 who are biomarker negative and clinically asymptomatic (Table 5). The rationale is that
650 an individual with DSAD or ADAD has the disease from birth, prior to onset of brain pathologic
651 change or symptoms. A person with DSAD or ADAD would move from stage 0 into stage 1
652 when a core biomarker became positive. The idea of stage 0 as genetically determined disease
653 which has not yet manifest clinically or with biomarkers is conceptually consistent with recent
654 staging proposals for Huntington’s and Parkinson’s disease 110-113.
655 We have not included AD risk alleles in the staging scheme. Unlike autosomal dominate
656 mutations which have 100% penetrance (barring premature death from other causes), carriers of
657 risk alleles including some APOE e4/4 individuals, may survive to late life without developing
658 fully manifest AD pathologic change or symptoms. We therefore regard risk alleles as just that,
659 and not a stage of AD.
660
661 5.3) Syndromic staging
662 The 2018 document also included a syndromic staging scheme that is commonly used in
663 clinical practice 186,187 and consists of 3 clinically defined stages: cognitively unimpaired (CU);
664 mild cognitive impairment (MCI); and dementia. Numeric clinical stages 1 and 2 correspond to
665 CU; numeric stage 3 roughly corresponds to MCI although the MCI syndrome would apply to
666 some individuals in stage 2 as well; numeric stages 4, 5 and 6 correspond to mild, moderate, and
667 severe dementia respectively. Unlike numeric clinical staging, syndromic staging is not
668 conditioned on a biological AD diagnosis and is applicable to individuals who are and who are
669 not in the AD continuum.
Page 22 of 39
670
671
672 6) Integrated biological and clinical staging
673 As in the 2018 framework we distinguish between clinical staging and biological disease
674 staging. These are regarded as quasi-independent variables. The symptomatic consequence of
675 biological AD is modified by interindividual differences in co-pathologies, resistance, and
676 reserve (i.e., education other social determinants of health) 188,189. Consequently, the degree of
677 cognitive/functional impairment does not follow in lock step with biological AD severity - i.e., a
678 range of possible relationships between biological AD stage and clinical stage will be found
679 across the population (Figure 1). While clinical staging and biological staging must be
680 performed independently, these two types of staging information can be integrated while still
681 preserving independence of content.
682 We propose an integrated biological and clinical staging scheme outlined in Table 6. As
683 with biological staging, the integrated staging scheme is only applicable to individuals diagnosed
684 with AD by core biomarkers. In Table 6, clinical stages are denoted in the columns using the
685 numeric 6-stage scheme plus stage 0. Biological stages are denoted in the rows. Integrated stages
686 appear in the cells. This display format is intended to convey the concept that biological AD
687 stage and clinical severity are related, but do not travel in lockstep. The typical or average
688 relationship between biology and symptoms can be envisioned as moving along an upper left to
689 lower right diagonal (the shaded cells) in Table 6, but considerable variation will occur in the
690 population. Individuals who lie above the diagonal (i.e., worse clinical stage than expected for
691 biological stage) are expected to have greater co morbid pathologic change. Individuals who lie
692 below the diagonal (i.e., better clinical stage than expected for biological stage) may have
693 exceptional resistance or cognitive reserve.
694 To avoid confusion when integrating numeric clinical staging with biological staging, we
695 use numbers for clinical staging and letters for biological staging (Table 6). For example,
696 clinical stage 2 and biological stage a is integrated stage 2a. If the biological stage was
697 ascertained with PET this would appear as integrated stage 2Pa and if by fluid as stage 2Fa.
698
699
Page 23 of 39
700 7) Multi-modal biomarker profiles and identification of comorbid pathologic change
701 We distinguish multi-modal biomarker “profiles” from AD biological staging. Biomarker

702 profiles may employ core and non-core biomarkers to characterize the general pathophysiologic
703 state of an individual beyond or in addition to the presence of AD. Biological staging of AD
704 applies only to individuals in whom AD has been detected by core biomarkers, in contrast
705 biomarker profiles are applicable to all individuals in the population.
706 Using biomarkers outlined in Tables 1-3, a full multimodal biomarker profile would
707 appear as ATNISV with +/- indicated as appropriate to each category. Full profiles require
708 extensive biomarker phenotyping; however, partial profiles are more likely to be available and
709 may be useful conceptually and in clinical practise to characterize individuals.
710 One potential use of multimodal biomarker profiles is to provide simple conceptual
711 organization and practical shorthand notation to characterize persons with multiple coexistent
712 pathologies. With advancing age, co-pathologies are the rule and isolated AD is the exception.
713 The four most common age-related brain pathologies that underlie cognitive impairment or
714 dementia in elderly persons are AD, cerebrovascular disease (CVD), limbic associated TDP-43
715 encephalopathy (LATE), and Lewy Body disease 89,190-192. Direct indicators of co-pathology
716 would be a positive SAA assay (A+T+S+) or multiple infarctions (A+T+V+) in someone who
717 also had biomarker evidence of AD. There are, however, several useful indirect indicators that
718 one or more non-AD co-pathologies likely is present.
719 To this point we have not emphasized N biomarkers, but a useful indirect indicator of
720 copathology is a “TN” mismatch in an ATN profile 193-196. Neurodegeneration in AD is closely
721 related in time and topography to tau deposition. T-N+ biomarker profiles (i.e., TN mismatch)
722 therefore indicate the presence of neurodegeneration or neuronal injury due to a disease(s) other
723 than AD. An archetypical example of this is an older person presenting with a progressive
724 memory problem and an A+T-N+ biomarker profile (where N+ is represented by severe medial
725 temporal lobe atrophy on MR or hypometabolism on PET) (Figure 1, 2). Such a person has AD
726 biological stage a (denoted by A+T-), but in addition likely also has LATE disease (denoted by
727 N+) with the latter likely responsible for current symptoms 104. TN mismatches in the opposite
728 direction (i.e., less N than expected for the degree of T) may be an indicator of an individual with
729 exceptional resistance to the effects of AD tauopathy. Similar logic could be applied to T-I+
Page 24 of 39
730 mismatches in individuals who are A+, although much less experience is currently available with
731 I biomarkers compared with the N category.
732 If an individual with abnormal AD biomarkers also presents with classic signs and
733 symptoms of a common non-AD disease, for example Parkinsonism, then it is likely that person
734 has synucleinopathy in addition to AD. It is likely that AD is not the sole explanation for
735 cognitive deficits in such a person, but without a quantitative biomarker of synucleinopathy,
736 assigning a “proportion of cognitive deficit” attributable to AD vs synucleinopathy is not
737 realistic.
738 Newer image data analysis methods may be useful in identifying likely copathologies 197.
739
740 7.1) Use cases
741 Indicators of co-pathology may be useful in clinical diagnosis, prognosis, and treatment
742 decisions. For example, a cognitively impaired individual with an A+T- N+ biomarker profile
743 may track more like LATE disease than AD clinically and may not respond to anti Aβ
744 immunotherapy in the same manner as someone who has an A+T+N- or A+T-N- biomarker
745 profile.
746 In clinical trials, indicators of co pathology could be used as exclusionary criteria,
747 particularly phase 2 trials which are often not fully powered to see clinical benefit and where a
748 biologically homogeneous cohort with purer AD is desirable. Alternately individuals with
749 indicators of co-pathology could be included in AD trials and analyzed in preplanned subset
750 analyses, particularly phase 3 trials, with the goal of creating registration trial populations that
751 are more generalizable. Identification of co-pathologies to subset AD in research cohorts may
752 also lead to a better understanding of the genetic underpinnings of the disease.
753
754
755
756 8) Treatment effects
757 The focus of this document is on criteria for diagnosis and staging of AD; detailed
758 discussion of the roles of biomarkers as a outcome measures or indicators of target engagement
759 in clinical trials is beyond the scope of this work. Nonetheless, the recent regulatory approval of
Page 25 of 39
760 disease targeted therapies promises to be transformative. Anti Aβ immunotherapy can

761 dramatically reduce the load of amyloid plaque in a time and dose dependent manner and also
762 may move downstream biomarkers in the direction of normalization, including fluid ptau and
763 total tau (CSF, plasma or both) 198-200, plasma GFAP 198,200, and may also slow the rate of
764 accumulation on tau PET 198 [add donan when published]. Most importantly, recent trials have
765 demonstrated that anti Aβ immunotherapy, that reduces fibrillar amyloid levels measured on
766 PET imaging, can slow the rate of cognitive decline in early symptomatic AD 64,177,198,199. There
767 is consistency across both successful and failed immunotherapy agents that the amount of
768 amyloid PET reduction is associated with the degree of clinical benefit 64,201. These findings
769 linking biology to clinical manifestations, which have been replicated across independent
770 therapeutic programs 177,198,199, provide solid empiric support for a biological definition of AD.
771 While β-amyloid may be reduced to sub detection threshold levels on PET, this does not
772 mean that the disease has been eradicated, or that fibrillar amyloid forms are solely responsible
773 for cognitive impairment. Individuals followed after cessation of Aβ immunotherapy have shown
774 reversal of CSF Aβ 42/40 normalization, some clinical progression, and eventual recurrent
775 accumulation of amyloid on PET 202. The underlying AD pathophysiologic process is therefore
776 still active in an individual who has had fibrillar amyloid removed to below detection levels. The
777 biological diagnosis and staging schemes outlined earlier are based on the order of biomarker
778 events observed in the natural history of the disease. Disease targeted therapies may alter the
779 relationships among biomarkers that are present in the natural evolution of the disease. For
780 example, an individual who has been treated with an anti Aβ monoclonal antibody may change
781 from A+T+ at baseline to A-T+ following treatment. The staging schemes we outlined earlier
782 therefore should be regarded as tools for diagnosis, staging/prognosis, and treatment assignment
783 pretreatment but not as indicators of the stage of the natural history of the disease post treatment.
784 Anti Aβ immuno therapy often results in higher rates of whole brain volume loss or
785 ventricular enlargement in treated vs placebo individuals 177,199,203. Explanations for this include
786 therapy induced fluid shifts, reduction in volume of amyloid plaque, or reduction in peri-plaque
787 inflammation. It has become apparent that slowing of the rate of volume loss by successful
788 amyloid removal, which was anticipated based on natural history studies, is not seen in the
789 relatively short duration of most clinical trials. Slowing of atrophy rates may occur over much
790 longer time scales with successful therapy, but this remains to be shown. MRI can only be
Page 26 of 39
791 considered a measure of neurodegeneration in conditions of physiologic steady state – i.e., in the
792 absence of abrupt changes in tissue water concentration or edema – which seems not to be the
793 case during active anti Aβ immuno therapy. MR does have an important role in anti-amyloid
794 therapy in trials and in clinical use as means of identifying amyloid imaging related
795 abnormalities (ARIA) for safety purposes 204. ARIA E (edema) is identified best with FLAIR
796 images while ARIA H (hemorrhage) is best identified with some variant of gradient recalled
797 echo imaging 205.
798
799
800 9) Diversity and need for more representative cohorts
801 The need for more representative cohorts for observational studies and clinical trials has
802 been pointed out repeatedly and the committee endorses this position 38,206-208. The biomarkers
803 described in this document have not yet been extensively tested in broadly representative
804 populations and further analysis in these groups is needed. Representative research cohorts are
805 needed to assess if treatments are effective across a range of social determinants of health
806 (SDOH) 132,209,210. SDOH may also modify the predictive effect of biomarkers for cognitive
807 decline. The interaction between biomarkers and genetic markers may differ by race. For
808 example, the effect of APOE e4 on amyloid deposition repeatedly observed in White
809 populations, may not be as strong in Black populations 211, and Asian populations have lower
810 prevalence of APOE e4. Representativeness encompasses many factors, including race and
811 ethnicity, but also socio-economic status, education, geographic location, lifestyle, and other
812 SDOH. Notions of racial/ethnic representativeness are country specific. In contrast, lower
813 education and socio-economic status are universal barriers to inclusion in research studies that
814 are present in all countries.
815
816
817 10) Future Directions
818 The series of NIA AA documents from 2011 to the present have focused on diagnosis and
819 characterization of AD. Over the past several decades the field has moved from diagnosing and
Page 27 of 39
820 characterizing the disease based on clinical presentation, to diagnosing the disease biologically
821 like most other major diseases. Biologically based diagnosis and staging is now transitioning
822 from priorities dominated by research to the priorities required for clinical practice. Biological
823 diagnosis and staging of AD in clinical practice will require substantial efforts around
824 standardization and wider availability of fluid and PET biomarkers. Future directions to consider
825 for updating these NIA AA clinical criteria could include the following. Identify more specific
826 criteria for fluid assay and PET technical and clinical validation performance. Select specific
827 quantitative criteria for cutpoints to define stages for fluid and PET. Link imaging and fluid
828 biological staging of AD. Like biomarker and imaging standards in other diseases, such as
829 cholesterol markers for vascular risk, glucose and HgbA1c for diabetes, and imaging for cancer
830 staging, the exact thresholds for abnormality may evolve over time, as additional data inform the
831 prognostic value of these cutpoints beginning at even earlier stage of disease. Improved
832 understanding of various post translational modifications of tau will likely lead to modifications
833 in fluid based biological staging. With improved understanding of the role of inflammatory
834 processes in AD pathogenesis 64-66, we envision a more prominent role for I biomarkers in
835 biological characterization and prognosis. Observational studies and clinical trials should be
836 conducted with more diverse and representative cohorts. We envision creating a comprehensive
837 system to stratify risk of progression by incorporating all biomarkers (core AD, non-core, and
838 biomarkers of non-AD copathology) along with demographics and genetics. However, all these
839 goals will depend first on standardization/harmonization of biofluid assays, standardized
840 quantification of tau PET, and standardization of cutpoints for all fluid and PET biomarkers.
841
842 1. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's
843 disease: recommendations from the National Institute on Aging-Alzheimer's Assocation
844 workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3):280-
845 292.
846 2. Albert MS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to
847 Alzheimer's disease: Recommendations from the National Institute on Aging and Alzheimer's
848 Association Workgroup. Alzheimers Dement. 2011;7(3):270-279.
849 3. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's
850 disease: Recommendations from the National Institute on Aging and the Alzheimer's Assocation
851 Workgroup. Alzheimers Dement. 2011;7(3):263-269.
Page 28 of 39
852 4. Hyman BT, Phelps CH, Beach TG, et al. National Institute on Aging-Alzheimer's Association
853 guidelines for the neuropathologic assessment of Alzheimer's disease. Alzheimers Dement.
854 2012;8(1):1-13.
855 5. Montine TJ, Phelps CH, Beach TG, et al. National Institute on Aging-Alzheimer's Association
856 guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta
857 Neuropathol. 2012;123(1):1-11.
858 6. Jack CR, Jr., Bennett DA, Blennow K, et al. NIA-AA Research Framework: Toward a biological
859 definition of Alzheimer's disease. Alzheimers Dement. 2018;14(4):535-562.
860 7. Lowe VJ, Lundt ES, Albertson SM, et al. Neuroimaging correlates with neuropathologic schemes
861 in neurodegenerative disease. Alzheimers Dement. 2019;15(7):927-939.
862 8. La Joie R, Ayakta N, Seeley WW, et al. Multisite study of the relationships between antemortem
863 [(11)C]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease
864 neuropathology. Alzheimers Dement. 2019;15(2):205-216.
865 9. Clark CM, Pontecorvo MJ, Beach TG, et al. Cerebral PET with florbetapir compared with
866 neuropathology at autopsy for detection of neuritic amyloid-beta plaques: a prospective cohort
867 study. Lancet Neurol. 2012;11(8):669-678.
868 10. Murray ME, Lowe VJ, Graff-Radford NR, et al. Clinicopathologic and 11C-Pittsburgh compound B
869 implications of Thal amyloid phase across the Alzheimer's disease spectrum. Brain. 2015;138(Pt
870 5):1370-1381.
871 11. Thal DR, Beach TG, Zanette M, et al. [(18)F]flutemetamol amyloid positron emission tomography
872 in preclinical and symptomatic Alzheimer's disease: Specific detection of advanced phases of
873 amyloid-beta pathology. Alzheimers Dement. 2015;11(8):975-985.
874 12. Lowe VJ, Lundt ES, Albertson SM, et al. Tau-positron emission tomography correlates with
875 neuropathology findings. Alzheimers Dement. 2019.
876 13. Fleisher AS, Pontecorvo MJ, Devous MD, Sr., et al. Positron Emission Tomography Imaging With
877 [18F]flortaucipir and Postmortem Assessment of Alzheimer Disease Neuropathologic Changes.
878 JAMA Neurol. 2020;77(7):829-839.
879 14. Teunissen CE, Verberk IMW, Thijssen EH, et al. Blood-based biomarkers for Alzheimer's disease:
880 towards clinical implementation. Lancet Neurol. 2022;21(1):66-77.
881 15. Frisoni GB, Boccardi M, Barkhof F, et al. Strategic roadmap for an early diagnosis of Alzheimer's
882 disease based on biomarkers. Lancet Neurol. 2017;16(8):661-676.
883 16. Villemagne VL, Lopresti BJ, Dore V, et al. What Is T+? A Gordian Knot of Tracers, Thresholds, and
884 Topographies. J Nucl Med. 2021;62(5):614-619.
885 17. Mattsson-Carlgren N, Andersson E, Janelidze S, et al. Abeta deposition is associated with
886 increases in soluble and phosphorylated tau that precede a positive Tau PET in Alzheimer's
887 disease. Sci Adv. 2020;6(16):eaaz2387.
888 18. Barthelemy NR, Li Y, Joseph-Mathurin N, et al. A soluble phosphorylated tau signature links tau,
889 amyloid and the evolution of stages of dominantly inherited Alzheimer's disease. Nat Med.
890 2020;26(3):398-407.
891 19. Janelidze S, Berron D, Smith R, et al. Associations of Plasma Phospho-Tau217 Levels With Tau
892 Positron Emission Tomography in Early Alzheimer Disease. JAMA Neurol. 2020.
893 20. Therriault J, Pascoal T, Lussier F, et al. Biomarker modeling of Alzheimer’s disease using PET-
894 based Braak staging. nature aging. 2022;online ahead of print.
895 21. Groot C, Smith R, Stomrud E, et al. Phospho-tau with subthreshold tau-PET predicts increased
896 tau accumulation rates in amyloid-positive individuals. Brain. 2023;146(4):1580-1591.
897 22. Ossenkoppele R, Reimand J, Smith R, et al. Tau PET correlates with different Alzheimer's disease-
898 related features compared to CSF and plasma p-tau biomarkers. EMBO Mol Med.
899 2021;13(8):e14398.
Page 29 of 39
900 23. Leuzy A, Smith R, Cullen NC, et al. Biomarker-Based Prediction of Longitudinal Tau Positron
901 Emission Tomography in Alzheimer Disease. JAMA Neurol. 2022;79(2):149-158.
902 24. Sato C, Barthelemy NR, Mawuenyega KG, et al. Tau Kinetics in Neurons and the Human Central
903 Nervous System. Neuron. 2018;98(4):861-864.
904 25. Hansson O, Seibyl J, Stomrud E, et al. CSF biomarkers of Alzheimer's disease concord with
905 amyloid-beta PET and predict clinical progression: A study of fully automated immunoassays in
906 BioFINDER and ADNI cohorts. Alzheimers Dement. 2018;14(11):1470-1481.
907 26. Ovod V, Ramsey KN, Mawuenyega KG, et al. Amyloid beta concentrations and stable isotope
908 labeling kinetics of human plasma specific to central nervous system amyloidosis. Alzheimers
909 Dement. 2017;13(8):841-849.
910 27. Nakamura A, Kaneko N, Villemagne VL, et al. High performance plasma amyloid-β biomarkers
911 for Alzheimer’s disease. Nature. 2018;554(7691):249-254.
912 28. Schindler SE, Bollinger JG, Ovod V, et al. High-precision plasma beta-amyloid 42/40 predicts
913 current and future brain amyloidosis. Neurology. 2019.
914 29. Mielke MM, Hagen CE, Xu J, et al. Plasma phospho-tau181 increases with Alzheimer's disease
915 clinical severity and is associated with tau- and amyloid-positron emission tomography.
916 Alzheimers Dement. 2018;14(8):989-997.
917 30. Janelidze S, Mattsson N, Palmqvist S, et al. Plasma P-tau181 in Alzheimer's disease: relationship
918 to other biomarkers, differential diagnosis, neuropathology and longitudinal progression to
919 Alzheimer's dementia. Nat Med. 2020;26(3):379-386.
920 31. Karikari TK, Pascoal TA, Ashton NJ, et al. Blood phosphorylated tau 181 as a biomarker for
921 Alzheimer's disease: a diagnostic performance and prediction modelling study using data from
922 four prospective cohorts. Lancet Neurol. 2020;19(5):422-433.
923 32. Palmqvist S, Janelidze S, Quiroz YT, et al. Discriminative Accuracy of Plasma Phospho-tau217 for
924 Alzheimer Disease vs Other Neurodegenerative Disorders. JAMA Neurol. 2020;324(8):772-781.
925 33. Thijssen EH, La Joie R, Wolf A, et al. Diagnostic value of plasma phosphorylated tau181 in
926 Alzheimer's disease and frontotemporal lobar degeneration. Nat Med. 2020;26(3):387-397.
927 34. Palmqvist S, Tideman P, Cullen N, et al. Prediction of future Alzheimer's disease dementia using
928 plasma phospho-tau combined with other accessible measures. Nat Med. 2021;27(6):1034-
929 1042.
930 35. Therriault J, Benedet AL, Pascoal TA, et al. Association of plasma P-tau181 with memory decline
931 in non-demented adults. Brain Commun. 2021;3(3):fcab136.
932 36. Moscoso A, Grothe MJ, Ashton NJ, et al. Longitudinal Associations of Blood Phosphorylated
933 Tau181 and Neurofilament Light Chain With Neurodegeneration in Alzheimer Disease. JAMA
934 Neurol. 2021;Online ahead of print.
935 37. Moscoso A, Grothe MJ, Ashton NJ, et al. Time course of phosphorylated-tau181 in blood across
936 the Alzheimer's disease spectrum. Brain. 2020;Online ahead of print.
937 38. Brickman AM, Manly JJ, Honig LS, et al. Plasma p-tau181, p-tau217, and other blood-based
938 Alzheimer's disease biomarkers in a multi-ethnic, community study. Alzheimers Dement.
939 2021;Online Ahead of Print.
940 39. Thijssen EH, Verberk IMW, Kindermans J, et al. Differential diagnostic performance of a panel of
941 plasma biomarkers for different types of dementia. Alzheimers Dement (Amst).
942 2022;14(1):e12285.
943 40. Janelidze S, Bali D, Ashton NJ, et al. Head-to-head comparison of 10 plasma phospho-tau assays
944 in prodromal Alzheimer's disease. Brain. 2022;awac333.
945 41. Janelidze S, Teunissen CE, Zetterberg H, et al. Head-to-Head Comparison of 8 Plasma Amyloid-
946 beta 42/40 Assays in Alzheimer Disease. JAMA Neurol. 2021;78(11):1375-1382.
Page 30 of 39
947 42. Barthelemy NR, Bateman RJ, Hirtz C, et al. Cerebrospinal fluid phospho-tau T217 outperforms
948 T181 as a biomarker for the differential diagnosis of Alzheimer's disease and PET amyloid-
949 positive patient identification. Alzheimers Res Ther. 2020;12(1):26.
950 43. Hansson O. Biomarkers for neurodegenerative diseases. Nat Med. 2021;27(6):954-963.
951 44. Bridel C, van Wieringen WN, Zetterberg H, et al. Diagnostic Value of Cerebrospinal Fluid
952 Neurofilament Light Protein in Neurology: A Systematic Review and Meta-analysis. JAMA
953 Neurol. 2019.
954 45. Mielke MM, Syrjanen JA, Blennow K, et al. Plasma and CSF neurofilament light: Relation to
955 longitudinal neuroimaging and cognitive measures. Neurology. 2019;93(3):e252-e260.
956 46. Mattsson N, Andreasson U, Zetterberg H, Blennow K. Association of Plasma Neurofilament Light
957 With Neurodegeneration in Patients With Alzheimer Disease. JAMA Neurol. 2017;74(5):557-566.
958 47. Mattsson N, Cullen NC, Andreasson U, Zetterberg H, Blennow K. Association Between
959 Longitudinal Plasma Neurofilament Light and Neurodegeneration in Patients With Alzheimer
960 Disease. JAMA Neurol. 2019;76(7):791-799.
961 48. Ashton NJ, Hye A, Rajkumar AP, et al. An update on blood-based biomarkers for non-Alzheimer
962 neurodegenerative disorders. Nat Rev Neurol. 2020;16(5):265-284.
963 49. Mattsson-Carlgren N, Janelidze S, Palmqvist S, et al. Longitudinal plasma p-tau217 is increased in
964 early stages of Alzheimer's disease. Brain. 2020;143(11):3234-3241.
965 50. Chatterjee P, Pedrini S, Ashton NJ, et al. Diagnostic and prognostic plasma biomarkers for
966 preclinical Alzheimer's disease. Alzheimers Dement. 2022;18(6):1141-1154.
967 51. Benedet AL, Leuzy A, Pascoal TA, et al. Stage-specific links between plasma neurofilament light
968 and imaging biomarkers of Alzheimer's disease. Brain. 2020;143(12):3793-3804.
969 52. Verberk IMW, Laarhuis MB, van den Bosch KA, et al. Serum markers glial fibrillary acidic protein
970 and neurofilament light for prognosis and monitoring in cognitively normal older people: a
971 prospective memory clinic-based cohort study. Lancet Healthy Longev. 2021;2(2):e87-e95.
972 53. Zetterberg H, Blennow K. Moving fluid biomarkers for Alzheimer's disease from research tools to
973 routine clinical diagnostics. Mol Neurodegener. 2021;16(1):10.
974 54. Kmezic I, Samuelsson K, Finn A, et al. Neurofilament light chain and total tau in the differential
975 diagnosis and prognostic evaluation of acute and chronic inflammatory polyneuropathies.
976 European journal of neurology. 2022;29(9):2810-2822.
977 55. Bobinski M, de Leon MJ, Wegiel J, et al. The histological validation of post mortem magnetic
978 resonance imaging-determined hippocampal volume in Alzheimer's disease. Neuroscience.
979 2000;95(3):721-725.
980 56. Zarow C, Vinters HV, Ellis WG, et al. Correlates of hippocampal neuron number in Alzheimer's
981 disease and ischemic vascular dementia. Ann Neurol. 2005;57(6):896-903.
982 57. Jack CR, Jr., Dickson DW, Parisi JE, et al. Antemortem MRI findings correlate with hippocampal
983 neuropathology in typical aging and dementia. Neurology. 2002;58(5):750-757.
984 58. Jagust WJ, Zheng L, Harvey DJ, et al. Neuropathological basis of magnetic resonance images in
985 aging and dementia. Ann Neurol. 2008;63(1):72-80.
986 59. Finnema SJ, Nabulsi NB, Eid T, et al. Imaging synaptic density in the living human brain. Sci Transl
987 Med. 2016;8(348):348ra396.
988 60. Chen MK, Mecca AP, Naganawa M, et al. Assessing Synaptic Density in Alzheimer Disease With
989 Synaptic Vesicle Glycoprotein 2A Positron Emission Tomographic Imaging. JAMA Neurol.
990 2018;75(10):1215-1224.
991 61. Mecca AP, Chen MK, O'Dell RS, et al. In vivo measurement of widespread synaptic loss in
992 Alzheimer's disease with SV2A PET. Alzheimers Dement. 2020;16(7):974-982.
Page 31 of 39
993 62. Li S, Naganawa M, Pracitto R, et al. Assessment of test-retest reproducibility of [(18)F]SynVesT-

994 1, a novel radiotracer for PET imaging of synaptic vesicle glycoprotein 2A. Eur J Nucl Med Mol
995 Imaging. 2021;48(5):1327-1338.
996 63. Gouw AA, Alsema AM, Tijms BM, et al. EEG spectral analysis as a putative early prognostic
997 biomarker in nondemented, amyloid positive subjects. Neurobiol Aging. 2017;57:133-142.
998 64. Haass C, Selkoe D. If amyloid drives Alzheimer disease, why have anti-amyloid therapies not yet
999 slowed cognitive decline? PLoS Biol. 2022;20(7):e3001694.
1000 65. De Strooper B, Karran E. The Cellular Phase of Alzheimer's Disease. Cell. 2016;164(4):603-615.
1001 66. Bouzid H, Belk JA, Jan M, et al. Clonal hematopoiesis is associated with protection from
1002 Alzheimer's disease. Nat Med. 2023.
1003 67. Cummings J, Lee G, Zhong K, Fonseca J, Taghva K. Alzheimer's disease drug development
1004 pipeline: 2021. Alzheimers Dement (N Y). 2021;7(1):e12179.
1005 68. Chatterjee P, Vermunt L, Gordon BA, et al. Plasma glial fibrillary acidic protein in autosomal
1006 dominant Alzheimer's disease: Associations with Abeta-PET, neurodegeneration, and cognition.
1007 Alzheimers Dement. 2022.
1008 69. Abdelhak A, Foschi M, Abu-Rumeileh S, et al. Blood GFAP as an emerging biomarker in brain and
1009 spinal cord disorders. Nat Rev Neurol. 2022;18(3):158-172.
1010 70. Mila-Aloma M, Ashton N, Shekari M, et al. Plasma p-tau231 and p-tau217 as state markers of
1011 amyloid-β pathology in preclinical Alzheimer’s disease. Nat Med.Embargo.
1012 71. O'Connor A, Abel E, Benedet AL, et al. Plasma GFAP in presymptomatic and symptomatic familial
1013 Alzheimer's disease: a longitudinal cohort study. J Neurol Neurosurg Psychiatry. 2022.
1014 72. Pereira JB, Janelidze S, Smith R, et al. Plasma GFAP is an early marker of amyloid-beta but not
1015 tau pathology in Alzheimer's disease. Brain. 2021;144(11):3505-3516.
1016 73. Suarez-Calvet M, Araque Caballero MA, Kleinberger G, et al. Early changes in CSF sTREM2 in
1017 dominantly inherited Alzheimer's disease occur after amyloid deposition and neuronal injury. Sci
1018 Transl Med. 2016;8(369):369ra178.
1019 74. Morenas-Rodriguez E, Li Y, Nuscher B, et al. Soluble TREM2 in CSF and its association with other
1020 biomarkers and cognition in autosomal-dominant Alzheimer's disease: a longitudinal
1021 observational study. Lancet Neurol. 2022;21(4):329-341.
1022 75. Fairfoul G, McGuire LI, Pal S, et al. Alpha-synuclein RT-QuIC in the CSF of patients with alpha-
1023 synucleinopathies. Ann Clin Transl Neurol. 2016;3(10):812-818.
1024 76. Shahnawaz M, Tokuda T, Waragai M, et al. Development of a Biochemical Diagnosis of Parkinson
1025 Disease by Detection of alpha-Synuclein Misfolded Aggregates in Cerebrospinal Fluid. JAMA
1026 Neurol. 2017;74(2):163-172.
1027 77. Arnold MR, Coughlin DG, Brumbach BH, et al. alpha-Synuclein Seed Amplification in CSF and
1028 Brain from Patients with Different Brain Distributions of Pathological alpha-Synuclein in the
1029 Context of Co-Pathology and Non-LBD Diagnoses. Ann Neurol. 2022;92(4):650-662.
1030 78. Rossi M, Candelise N, Baiardi S, et al. Ultrasensitive RT-QuIC assay with high sensitivity and
1031 specificity for Lewy body-associated synucleinopathies. Acta Neuropathol. 2020;140(1):49-62.
1032 79. Bargar C, De Luca CMG, Devigili G, et al. Discrimination of MSA-P and MSA-C by RT-QuIC analysis
1033 of olfactory mucosa: the first assessment of assay reproducibility between two specialized
1034 laboratories. Mol Neurodegener. 2021;16(1):82.
1035 80. Poggiolini I, Gupta V, Lawton M, et al. Diagnostic value of cerebrospinal fluid alpha-synuclein
1036 seed quantification in synucleinopathies. Brain. 2022;145(2):584-595.
1037 81. Manne S, Kondru N, Jin H, et al. Blinded RT-QuIC Analysis of alpha-Synuclein Biomarker in Skin
1038 Tissue From Parkinson's Disease Patients. Mov Disord. 2020;35(12):2230-2239.
Page 32 of 39
1039 82. De Luca CMG, Elia AE, Portaleone SM, et al. Efficient RT-QuIC seeding activity for alpha-synuclein
1040 in olfactory mucosa samples of patients with Parkinson's disease and multiple system atrophy.
1041 Transl Neurodegener. 2019;8:24.
1042 83. Seibyl JP. alpha-Synuclein PET and Parkinson Disease Therapeutic Trials: Ever the Twain Shall
1043 Meet? J Nucl Med. 2022;63(10):1463-1466.
1044 84. Korat S, Bidesi NSR, Bonanno F, et al. Alpha-Synuclein PET Tracer Development-An Overview
1045 about Current Efforts. Pharmaceuticals (Basel). 2021;14(9).
1046 85. McKeith I, O'Brien J, Walker Z, et al. Sensitivity and specificity of dopamine transporter imaging
1047 with 123I-FP-CIT SPECT in dementia with Lewy bodies: a phase III, multicentre study. Lancet
1048 Neurol. 2007;6(4):305-313.
1049 86. Vlaar AM, de Nijs T, Kessels AG, et al. Diagnostic value of 123I-ioflupane and 123I-
1050 iodobenzamide SPECT scans in 248 patients with parkinsonian syndromes. Eur Neurol.
1051 2008;59(5):258-266.
1052 87. Nelson PT, Abner EL, Schmitt FA, et al. Modeling the Association between 43 Different Clinical
1053 and Pathological Variables and the Severity of Cognitive Impairment in a Large Autopsy Cohort
1054 of Elderly Persons. Brain Pathol. 2010;20(1):66-79.
1055 88. Kawas CH, Kim RC, Sonnen JA, Bullain SS, Trieu T, Corrada MM. Multiple pathologies are
1056 common and related to dementia in the oldest-old: The 90+ Study. Neurology. 2015;85(6):535-
1057 542.
1058 89. Power MC, Mormino E, Soldan A, et al. Combined neuropathological pathways account for age-
1059 related risk of dementia. Ann Neurol. 2018;84(1):10-22.
1060 90. Raman MR, Preboske GM, Przybelski SA, et al. Antemortem MRI findings associated with
1061 microinfarcts at autopsy. Neurology. 2014;82(22):1951-1958.
1062 91. van Veluw SJ, Shih AY, Smith EE, et al. Detection, risk factors, and functional consequences of
1063 cerebral microinfarcts. Lancet Neurol. 2017;16(9):730-740.
1064 92. Sleight E, Stringer MS, Marshall I, Wardlaw JM, Thrippleton MJ. Cerebrovascular Reactivity
1065 Measurement Using Magnetic Resonance Imaging: A Systematic Review. Front Physiol.
1066 2021;12:643468.
1067 93. Wardlaw JM, Benveniste H, Nedergaard M, et al. Perivascular spaces in the brain: anatomy,
1068 physiology and pathology. Nat Rev Neurol. 2020;16(3):137-153.
1069 94. Duering M, Biessels GJ, Brodtmann A, et al. Neuroimaging standards for research into small
1070 vessel disease-advances since 2013. Lancet Neurol. 2023;22(7):602-618.
1071 95. Baykara E, Gesierich B, Adam R, et al. A Novel Imaging Marker for Small Vessel Disease Based on
1072 Skeletonization of White Matter Tracts and Diffusion Histograms. Ann Neurol. 2016;80(4):581-
1073 592.
1074 96. Vemuri P, Graff-Radford J, Lesnick T, et al. White matter abnormalities are key components of
1075 cerebrovascular disease impacting cognitive decline. brain Commun. 2021;3(2).
1076 97. Vemuri P, Lesnick TG, Knopman DS, et al. Amyloid, Vascular, and Resilience Pathways Associated
1077 with Cognitive Aging. Ann Neurol. 2019.
1078 98. Vemuri P, Lesnick TG, Przybelski SA, et al. Development of a cerebrovascular magnetic
1079 resonance imaging biomarker for cognitive aging. Ann Neurol. 2018;84(5):705-716.
1080 99. Myoraku A, Klein G, Landau S, Tosun D, Alzheimer's Disease Neuroimaging I. Regional uptakes
1081 from early-frame amyloid PET and (18)F-FDG PET scans are comparable independent of disease
1082 state. Eur J Hybrid Imaging. 2022;6(1):2.
1083 100. Lin KJ, Hsiao IT, Hsu JL, et al. Imaging characteristic of dual-phase (18)F-florbetapir (AV-
1084 45/Amyvid) PET for the concomitant detection of perfusion deficits and beta-amyloid deposition
1085 in Alzheimer's disease and mild cognitive impairment. Eur J Nucl Med Mol Imaging.
1086 2016;43(7):1304-1314.
Page 33 of 39
1087 101. Sweeney MD, Sagare AP, Pachicano M, et al. A novel sensitive assay for detection of a biomarker
1088 of pericyte injury in cerebrospinal fluid. Alzheimers Dement. 2020;16(6):821-830.
1089 102. Greenberg SM, Bacskai BJ, Hernandez-Guillamon M, Pruzin J, Sperling R, van Veluw SJ. Cerebral
1090 amyloid angiopathy and Alzheimer disease - one peptide, two pathways. Nat Rev Neurol.
1091 2020;16(1):30-42.
1092 103. Graff-Radford J, Lesnick T, Rabinstein AA, et al. Cerebral Microbleed Incidence and Relationship
1093 to Amyloid Burden: The Mayo Clinic Study of Aging. Neurology. 2019.
1094 104. Nelson PT, Dickson DW, Trojanowski JQ, et al. Limbic-predominant age-related TDP-43
1095 encephalopathy (LATE): consensus working group report. Brain. 2019;142(6):1503-1527.
1096 105. Whitwell JL, Lowe VJ, Tosakulwong N, et al. [(18) F]AV-1451 tau positron emission tomography
1097 in progressive supranuclear palsy. Mov Disord. 2017;32(1):124-133.
1098 106. Schonhaut DR, McMillan CT, Spina S, et al. (18) F-flortaucipir tau positron emission tomography
1099 distinguishes established progressive supranuclear palsy from controls and Parkinson disease: A
1100 multicenter study. Ann Neurol. 2017;82(4):622-634.
1101 107. Tezuka T, Takahata K, Seki M, et al. Evaluation of [(18)F]PI-2620, a second-generation selective
1102 tau tracer, for assessing four-repeat tauopathies. Brain Commun. 2021;3(4):fcab190.
1103 108. Graff-Radford J, Gunter JL, Jones DT, et al. Cerebrospinal fluid dynamics disorders: Relationship
1104 to Alzheimer biomarkers and cognition. Neurology. 2019;93(24):e2237-e2246.
1105 109. Crary JF, Trojanowski JQ, Schneider JA, et al. Primary age-related tauopathy (PART): a common
1106 pathology associated with human aging. Acta Neuropathol. 2014;128(6):755-766.
1107 110. Siderowf A, Concha-Marambio L, Lafontant D, et al. Assessment of heterogeneity among
1108 participants in the Parkinson’s Progression Markers Initiative cohort using α-synuclein seed
1109 amplification: a cross-sectional study. Lancet Neurol. 2023;22(5):407-417.
1110 111. Holinger GU, Adler CH, Berg D, et al. Towards a Biological Definition of Parkinson’s Disease.
1111 Preprints. 2023;Online ahead of print.
1112 112. Chahine LM, Merchant K, Siderowf A, et al. Proposal for a Biologic Staging System of Parkinson's
1113 Disease. J Parkinsons Dis. 2023;13(3):297-309.
1114 113. Tabrizi SJ, Schobel S, Gantman EC, et al. A biological classification of Huntington's disease: the
1115 Integrated Staging System. Lancet Neurol. 2022;21(7):632-644.
1116 114. Benatar M, Wuu J, McHutchison C, et al. Preventing amyotrophic lateral sclerosis: insights from
1117 pre-symptomatic neurodegenerative diseases. Brain. 2022;145(1):27-44.
1118 115. Curtis C, Gamez JE, Singh U, et al. Phase 3 trial of flutemetamol labeled with radioactive fluorine
1119 18 imaging and neuritic plaque density. JAMA Neurol. 2015;72(3):287-294.
1120 116. Sabri O, Sabbagh MN, Seibyl J, et al. Florbetaben PET imaging to detect amyloid beta plaques in
1121 Alzheimer's disease: phase 3 study. Alzheimers Dement. 2015;11(8):964-974.
1122 117. Kotari V, Southekal S, Navitsky M, et al. Early tau detection in flortaucipir images: validation in
1123 autopsy-confirmed data and implications for disease progression. Alzheimers Res Ther.
1124 2023;15(1):41.
1125 118. Salvado G, Ossenkoppele R, Ashton NJ, et al. Specific associations between plasma biomarkers
1126 and postmortem amyloid plaque and tau tangle loads. EMBO Mol Med. 2023;15(5):e17123.
1127 119. Villeneuve S, Rabinovici GD, Cohn-Sheehy BI, et al. Existing Pittsburgh Compound-B positron
1128 emission tomography thresholds are too high: statistical and pathological evaluation. Brain.
1129 2015;138(Pt 7):2020-2033.
1130 120. Landau SM, Horng A, Jagust WJ, Alzheimer's Disease Neuroimaging I. Memory decline
1131 accompanies subthreshold amyloid accumulation. Neurology. 2018;90(17):e1452-e1460.
1132 121. Farrell ME, Jiang S, Schultz AP, et al. Defining the Lowest Threshold for Amyloid-PET to Predict
1133 Future Cognitive Decline and Amyloid Accumulation. Neurology. 2021;96(4):e619-e631.
Page 34 of 39
1134 122. Fryback DG, Thornbury JR. The efficacy of diagnostic imaging. Med Decis Making. 1991;11(2):88-
1135 94.
1136 123. Schunemann HJ, Mustafa RA, Brozek J, et al. GRADE guidelines: 21 part 1. Study design, risk of
1137 bias, and indirectness in rating the certainty across a body of evidence for test accuracy. J Clin
1138 Epidemiol. 2020;122:129-141.
1139 124. Schunemann HJ, Mustafa RA, Brozek J, et al. GRADE guidelines: 21 part 2. Test accuracy:
1140 inconsistency, imprecision, publication bias, and other domains for rating the certainty of
1141 evidence and presenting it in evidence profiles and summary of findings tables. J Clin Epidemiol.
1142 2020;122:142-152.
1143 125. Schunemann HJ, Mustafa RA, Brozek J, et al. GRADE guidelines: 22. The GRADE approach for
1144 tests and strategies-from test accuracy to patient-important outcomes and recommendations. J
1145 Clin Epidemiol. 2019;111:69-82.
1146 126. Jack CR, Wiste HJ, Weigand SD, et al. Defining imaging biomarker cut points for brain aging and
1147 Alzheimer's disease. Alzheimers Dement. 2017;13(3):205-216.
1148 127. Sperling RA, Donohue MC, Raman R, et al. Association of Factors With Elevated Amyloid Burden
1149 in Clinically Normal Older individuals in the A4 Study Screening Cohort. JAMA Neurol. 2020.
1150 128. Farrell ME, Chen X, Rundle MM, Chan MY, Wig GS, Park DC. Regional amyloid accumulation and
1151 cognitive decline in initially amyloid-negative adults. Neurology. 2018;91(19):e1809-e1821.
1152 129. Sato C, Mallipeddi N, Ghoshal N, et al. MAPT R406W increases tau T217 phosphorylation in
1153 absence of amyloid pathology. Ann Clin Transl Neurol. 2021;8(9):1817-1830.
1154 130. Cousins KAQ, Shaw LM, Shellikeri S, et al. Elevated Plasma Phosphorylated Tau 181 in
1155 Amyotrophic Lateral Sclerosis. Ann Neurol. 2022;92(5):807-818.
1156 131. Mielke MM, Dage JL, Frank RD, et al. Performance of plasma phosphorylated tau 181 and 217 in
1157 the community. Nat Med. 2022.
1158 132. O'Bryant SE, Petersen M, Hall J, Johnson LA, Team H-HS. Medical comorbidities and ethnicity
1159 impact plasma Alzheimer's disease biomarkers: Important considerations for clinical trials and
1160 practice. Alzheimers Dement. 2023;19(1):36-43.
1161 133. Rabinovici GD, Gatsonis C, Apgar C, et al. Association of Amyloid Positron Emission Tomography
1162 With Subsequent Change in Clinical Management Among Medicare Beneficiaries With Mild
1163 Cognitive Impairment or Dementia. JAMA. 2019;321(13):1286-1294.
1164 134. Strikwerda-Brown C, Hobbs DA, Gonneaud J, et al. Association of Elevated Amyloid and Tau
1165 Positron Emission Tomography Signal With Near-Term Development of Alzheimer Disease
1166 Symptoms in Older Adults Without Cognitive Impairment. JAMA Neurol. 2022.
1167 135. Ebenau JL, Timmers T, Wesselman LMP, et al. ATN classification and clinical progression in
1168 subjective cognitive decline: The SCIENCe project. Neurology. 2020;95(1):e46-e58.
1169 136. Jack CR, Jr., Wiste HJ, Therneau TM, et al. Associations of Amyloid, Tau, and Neurodegeneration
1170 Biomarker Profiles With Rates of Memory Decline Among Individuals Without Dementia. JAMA.
1171 2019;321(23):2316-2325.
1172 137. Bellaver B, Povala G, Ferreira PCL, et al. Astrocyte reactivity influences amyloid-beta effects on
1173 tau pathology in preclinical Alzheimer's disease. Nat Med. 2023.
1174 138. Grothe MJ, Barthel H, Sepulcre J, et al. In vivo staging of regional amyloid deposition. Neurology.
1175 2017;89(20):2031-2038.
1176 139. Mattsson N, Palmqvist S, Stomrud E, Vogel J, Hansson O. Staging beta-Amyloid Pathology With
1177 Amyloid Positron Emission Tomography. JAMA Neurol. 2019;76(11):1319-1329.
1178 140. Collij LE, Heeman F, Salvado G, et al. Multitracer model for staging cortical amyloid deposition
1179 using PET imaging. Neurology. 2020;95(11):e1538-e1553.
1180 141. Johnson KA, Shultz A, Betensky RA, et al. Tau positron emission tomographic imaging in aging
1181 and early Alzheimer's disease. Ann Neurol. 2016;79(1):110-119.
Page 35 of 39
1182 142. Cho H, Choi JY, Hwang MS, et al. In vivo cortical spreading pattern of tau and amyloid in the
1183 Alzheimer disease spectrum. Ann Neurol. 2016;80(2):247-258.
1184 143. Scholl M, Lockhart SN, Schonhaut DR, et al. PET Imaging of tau deposition in the aging human
1185 brain. Neuron. 2016;89(5):971-982.
1186 144. Schwarz AJ, Shcherbinin S, Slieker LJ, et al. Topographic staging of tau positron emission
1187 tomography images. Alzheimers Dement (Amst). 2018;10:221-231.
1188 145. Jack CR, Wiste HJ, Algeciras-Schimnich A, et al. Predicting amyloid PET and tau PET stages with
1189 plasma biomarkers. Brain. 2023.
1190 146. Wang L, Benzinger TL, Su Y, et al. Evaluation of Tau Imaging in Staging Alzheimer Disease and
1191 Revealing Interactions Between beta-Amyloid and Tauopathy. JAMA Neurol. 2016;73(9):1070-
1192 1077.
1193 147. Villemagne VL, Dore V, Bourgeat P, et al. The Tau MeTeR Scale for the Generation of Continuous
1194 and Categorical Measures of Tau Deposits in the Brain: Results from 18F-AV1451 and 18F-
1195 THK5351 Tau Imaging Studies. Alzheimer's & dementia. 2016;12(7):244.
1196 148. Mintun MA, Larossa GN, Sheline YI, et al. [11C]PIB in a nondemented population: potential
1197 antecedent marker of Alzheimer disease. Neurology. 2006;67(3):446-452.
1198 149. Aizenstein HJ, Nebes RD, Saxton JA, et al. Frequent amyloid deposition without significant
1199 cognitive impairment among the elderly. Arch Neurol. 2008;65(11):1509-1517.
1200 150. Jack CR, Jr., Lowe VJ, Weigand SD, et al. Serial PIB and MRI in normal, mild cognitive impairment
1201 and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease.
1202 Brain. 2009;132(pt 5):1355-1365.
1203 151. Jack CR, Wiste HJ, Botha H, et al. The bivariate distribution of amyloid-beta and tau: relationship
1204 with established neurocognitive clinical syndromes. Brain. 2019;142(10):3230-3242.
1205 152. Guo T, Korman D, Baker SL, Landau SM, Jagust WJ, Alzheimer's Disease Neuroimaging I.
1206 Longitudinal Cognitive and Biomarker Measurements Support a Unidirectional Pathway in
1207 Alzheimer's Disease Pathophysiology. Biol Psychiatry. 2020.
1208 153. Ossenkoppele R, Schonhaut DR, Scholl M, et al. Tau PET patterns mirror clinical and
1209 neuroanatomical variability in Alzheimer's disease. Brain. 2016;139(5):1551-1567.
1210 154. Brier MR, Gordon B, Friedrichsen K, et al. Tau and Aβ imaging, CSF measures, and cognition in
1211 Alzheimer’s disease. Sci Transl Med. 2016;8(338):338ra366.
1212 155. Gordon BA, Blazey TM, Christensen J, et al. Tau PET in autosomal dominant Alzheimer's disease:
1213 relationship with cognition, dementia and other biomarkers. Brain. 2019;142(4):1063-1076.
1214 156. Jack CR, Jr., Knopman DS, Jagust WJ, et al. Hypothetical model of dynamic biomarkers of the
1215 Alzheimer's pathological cascade. Lancet Neurol. 2010;9(1):119-128.
1216 157. Bateman RJ, Xiong C, Benzinger TL, et al. Clinical and Biomarker Changes in Dominantly Inherited
1217 Alzheimer's Disease. The New England journal of medicine. 2012;367(9):795-804.
1218 158. Jack CR, Jr., Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer's
1219 disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol. 2013;12(2):207-
1220 216.
1221 159. Benzinger TL, Blazey T, Jack CR, Jr., et al. Regional variability of imaging biomarkers in autosomal
1222 dominant Alzheimer's disease. Proc Natl Acad Sci U S A. 2013;110(47):E4502-4509.
1223 160. Hanseeuw BJ, Betensky RA, Jacobs HIL, et al. Association of Amyloid and Tau With Cognition in
1224 Preclinical Alzheimer Disease: A Longitudinal Study. JAMA Neurol. 2019;76(8):915-924.
1225 161. Tetzloff KA, Graff-Radford J, Martin PR, et al. Regional Distribution, Asymmetry, and Clinical
1226 Correlates of Tau Uptake on [18F]AV-1451 PET in Atypical Alzheimer's Disease. J Alzheimers Dis.
1227 2018;62(4):1713-1724.
Page 36 of 39
1228 162. Farrell ME, Kennedy KM, Rodrigue KM, et al. Association of Longitudinal Cognitive Decline With
1229 Amyloid Burden in Middle-aged and Older Adults: Evidence for a Dose-Response Relationship.
1230 JAMA Neurol. 2017;74(7):830-838.
1231 163. Jack CR, Jr., Therneau TM, Lundt ES, et al. Long-term associations between amyloid positron
1232 emission tomography, sex, apolipoprotein E and incident dementia and mortality among
1233 individuals without dementia: hazard ratios and absolute risk. Brain Commun.
1234 2022;4(2):fcac017.
1235 164. Knopman DS, Lundt ES, Therneau TM, et al. Association of Initial beta-Amyloid Levels With
1236 Subsequent Flortaucipir Positron Emission Tomography Changes in Persons Without Cognitive
1237 Impairment. JAMA Neurol. 2021;78(2):217-228.
1238 165. Sanchez JS, Becker JA, Jacobs HIL, et al. The cortical origin and initial spread of medial temporal
1239 tauopathy in Alzheimer's disease assessed with positron emission tomography. Sci Transl Med.
1240 2021;13(577).
1241 166. Montoliu-Gaya L, Benedet AL, Tissot C, et al. Mass spectrometric simultaneous quantification of
1242 tau species in plasma shows differential associations with amyloid and tau pathologies. Nat
1243 Aging. 2023.
1244 167. Horie K, Barthelemy NR, Sato C, Bateman RJ. CSF tau microtubule binding region identifies tau
1245 tangle and clinical stages of Alzheimer's disease. Brain. 2021;144(2):515-527.
1246 168. Barthelemy NR, Saef B, Li Y, et al. CSF tau phosphorylation occupancies at T217 and T205
1247 represent improved biomarkers of amyloid and tau pathology in Alzheimer's disease. Nat Aging.
1248 2023;3(4):391-401.
1249 169. Vogel JW, Young AL, Oxtoby NP, et al. Four distinct trajectories of tau deposition identified in
1250 Alzheimer's disease. Nat Med. 2021.
1251 170. Ossenkoppele R, Smith R, Mattsson-Carlgren N, et al. Accuracy of Tau Positron Emission
1252 Tomography as a Prognostic Marker in Preclinical and Prodromal Alzheimer Disease: A Head-to-
1253 Head Comparison Against Amyloid Positron Emission Tomography and Magnetic Resonance
1254 Imaging. JAMA Neurol. 2021;78(8):961-971.
1255 171. Villemagne V, Leuzy A, Bohorquez SMS, et al. CenTauR: Towards a Universal Scale and Masks for
1256 Standardizing Tau Imaging Studies. 2023;in press Alz and Dem 2023.
1257 172. Klunk WE, Koeppe RA, Price JC, et al. The Centiloid Project: Standardizing quantitative amyloid
1258 plaque estimation by PET. Alzheimer's & dementia. 2015;11(1):1-15.
1259 173. Klunk WE, Price JC, Mathis CA, et al. Amyloid deposition begins in the striatum of presenilin-1
1260 mutation carriers from two unrelated pedigrees. J Neurosci. 2007;27(23):6174-6184.
1261 174. Cohen AD, McDade E, Christian B, et al. Early striatal amyloid deposition distinguishes Down
1262 syndrome and autosomal dominant Alzheimer's disease from late-onset amyloid deposition.
1263 Alzheimers Dement. 2018;14(6):743-750.
1264 175. Ossenkoppele R, Pichet Binette A, Groot C, et al. Amyloid and tau PET-positive cognitively
1265 unimpaired individuals are at high risk for future cognitive decline. Nat Med. 2022.
1266 176. Sperling RA, Mormino EC, Schultz AP, et al. The impact of amyloid-beta and tau on prospective
1267 cognitive decline in older individuals. Ann Neurol. 2019;85(2):181-193.
1268 177. Mintun MA, Lo AC, Duggan Evans C, et al. Donanemab in Early Alzheimer's Disease. N Engl J
1269 Med. 2021;384(18):1691-1704.
1270 178. Sperling RA, Rentz DM, Johnson KA, et al. The A4 study: stopping AD before symptoms begin?
1271 Sci Transl Med. 2014;6(228):228fs213.
1272 179. Rafii MS, Sperling RA, Donohue MC, et al. The AHEAD 3-45 Study: Design of a prevention trial for
1273 Alzheimer's disease. Alzheimers Dement. 2022;PMID: 35971310.
1274 180. Reisberg B, Ferris SH, de Leon MJ, Crook T. The Global Deterioration Scale for assessment of
1275 primary degenerative dementia. The American journal of psychiatry. 1982;139(9):1136-1139.
Page 37 of 39
1276 181. Dunn B. Early Alzheimer’s Disease: Developing Drugs for Treatment; Draft Guidance for Industry.
1277 2018;Services USDoHaH, Administration FaD, (CDER) CfDEaR, (CBER) CfBEaR, eds. Silver Spring,
1278 MD: Office of the Federal Register, National Archives and Records Administration:7060–7061.
1279 182. Ismail Z, Smith EE, Geda Y, et al. Neuropsychiatric symptoms as early manifestations of
1280 emergent dementia: Provisional diagnostic criteria for mild behavioral impairment. Alzheimers
1281 Dement. 2016;12(2):195-202.
1282 183. Graff-Radford J, Yong KXX, Apostolova LG, et al. New insights into atypical Alzheimer's disease in
1283 the era of biomarkers. Lancet Neurol. 2021;20(3):222-234.
1284 184. Dubois B, Villain N, Frisoni GB, et al. Clinical diagnosis of Alzheimer's disease: recommendations
1285 of the International Working Group. Lancet Neurol. 2021;20(6):484-496.
1286 185. Fortea J, Zaman SH, Hartley S, Rafii MS, Head E, Carmona-Iragui M. Alzheimer's disease
1287 associated with Down syndrome: a genetic form of dementia. Lancet Neurol. 2021;20(11):930-
1288 942.
1289 186. Roberts JS, Karlawish JH, Uhlmann WR, Petersen RC, Green RC. Mild cognitive impairment in
1290 clinical care: a survey of American Academy of Neurology members. Neurology. 2010;75(5):425-
1291 431.
1292 187. Bertens D, Vos S, Kehoe P, et al. Use of mild cognitive impairment and prodromal AD/MCI due to
1293 AD in clinical care: a European survey. Alzheimers Research & Therapy. 2019;11(1):74.
1294 188. Vemuri P, Lesnick TG, Przybelski SA, et al. Association of lifetime intellectual enrichment with
1295 cognitive decline in the older population. JAMA Neurol. 2014;71(8):1017-1024.
1296 189. Jagust WJ, Mormino EC. Lifespan brain activity, beta-amyloid, and Alzheimer's disease. Trends
1297 Cogn Sci. 2011;15(11):520-526.
1298 190. Nelson PT, Head E, Schmitt FA, et al. Alzheimer's disease is not "brain aging": neuropathological,
1299 genetic, and epidemiological human studies. Acta Neuropathol. 2011;121(5):571-587.
1300 191. Beach TG, Malek-Ahmadi M. Alzheimer's Disease Neuropathological Comorbidities are Common
1301 in the Younger-Old. J Alzheimers Dis. 2021;79(1):389-400.
1302 192. Petersen RC. How early can we diagnose Alzheimer disease (and is it sufficient)? The 2017
1303 Wartenberg lecture. Neurology. 2018;91(9):395-402.
1304 193. Botha H, Mantyh WG, Graff-Radford J, et al. Tau-negative amnestic dementia masquerading as
1305 Alzheimer disease dementia. Neurology. 2018;90(11):e940-e946.
1306 194. Botha H, Mantyh WG, Murray ME, et al. FDG-PET in tau-negative amnestic dementia resembles
1307 that of autopsy-proven hippocampal sclerosis. Brain. 2018;141(4):1201-1217.
1308 195. Duong MT, Das SR, Lyu X, et al. Dissociation of tau pathology and neuronal hypometabolism
1309 within the ATN framework of Alzheimer's disease. Nat Commun. 2022;13(1):1495.
1310 196. Lyu X, Duong MT, Xie L, et al. Tau-Neurodegeneration mismatch reveals vulnerability and
1311 resilience to comorbidities in Alzheimer's continuum. medRxiv. 2023.
1312 197. Jones D, Lowe V, Graff-Radford J, et al. A computational model of neurodegeneration in
1313 Alzheimer's disease. Nat Commun. 2022;13(1):1643.
1314 198. van Dyck CH, Swanson CJ, Aisen P, et al. Lecanemab in Early Alzheimer's Disease. N Engl J Med.
1315 2023;388(1):9-21.
1316 199. Budd Haeberlein S, Aisen PS, Barkhof F, et al. Two Randomized Phase 3 Studies of Aducanumab
1317 in Early Alzheimer's Disease. J Prev Alzheimers Dis. 2022;9(2):197-210.
1318 200. Pontecorvo MJ, Lu M, Burnham SC, et al. Association of Donanemab Treatment With
1319 Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease: A Secondary Analysis of
1320 the TRAILBLAZER-ALZ Randomized Clinical Trial. JAMA Neurol. 2022;79(12):1250-1259.
1321 201. FDA. Office of Neurology’s Summary Review Memorandum 2020. 2020.
Page 38 of 39
1322 202. McDade E, Cummings JL, Dhadda S, et al. Lecanemab in patients with early Alzheimer's disease:
1323 detailed results on biomarker, cognitive, and clinical effects from the randomized and open-
1324 label extension of the phase 2 proof-of-concept study. Alzheimers Res Ther. 2022;14(1):191.
1325 203. Novak G, Fox N, Clegg S, et al. Changes in Brain Volume with Bapineuzumab in Mild to Moderate
1326 Alzheimer's Disease. J Alzheimers Dis. 2016;49(4):1123-1134.
1327 204. Sperling R, Salloway S, Brooks DJ, et al. Amyloid-related imaging abnormalities in patients with
1328 Alzheimer's disease treated with bapineuzumab: a retrospective analysis. Lancet Neurol.
1329 2012;11(3):241-249.
1330 205. Cogswell PM, Barakos JA, Barkhof F, et al. Amyloid-Related Imaging Abnormalities with
1331 Emerging Alzheimer Disease Therapeutics: Detection and Reporting Recommendations for
1332 Clinical Practice. AJNR Am J Neuroradiol. 2022;43(9):E19-E35.
1333 206. Ighodaro ET, Nelson PT, Kukull WA, et al. Challenges and Considerations Related to Studying
1334 Dementia in Blacks/African Americans. J Alzheimers Dis. 2017;60(1):1-10.
1335 207. Babulal GM, Quiroz YT, Albensi BC, et al. Perspectives on ethnic and racial disparities in
1336 Alzheimer's disease and related dementias: Update and areas of immediate need. Alzheimers
1337 Dement. 2019;15(2):292-312.
1338 208. Brewster P, Barnes L, Haan M, et al. Progress and future challenges in aging and diversity
1339 research in the United States. Alzheimers Dement. 2019;15(7):995-1003.
1340 209. Schindler SE, Karikari TK, Ashton NJ, et al. Effect of Race on Prediction of Brain Amyloidosis by
1341 Plasma Abeta42/Abeta40, Phosphorylated Tau, and Neurofilament Light. Neurology.
1342 2022;99(3):e245-e257.
1343 210. Ramanan VK, Graff-Radford J, Syrjanan JA, et al. Association of Plasma Biomarkers of Alzheimer
1344 disease with Cognition and Medical Comorbidities in a Biracial Cohort. Neurology. 2023;In press.
1345 211. Deters KD, Napolioni V, Sperling RA, et al. Amyloid PET Imaging in Self-Identified Non-Hispanic
1346 Black Participants of the Anti-Amyloid in Asymptomatic Alzheimer's Disease (A4) Study.
1347 Neurology. 2021;96(11):e1491-e1500.
1348
We welcome your input, feedback and comments. Please submit through http://www.alz.org/nia-aa
Page 39 of 39

NIA AA Revised Clinical Criteria AAIC 2023

Uploaded by

Copyright:

Available Formats

NIA AA Revised Clinical Criteria AAIC 2023

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

NIA AA Revised Clinical Criteria AAIC 2023

Uploaded by

Copyright:

Available Formats

Website for feedback: alz.

DRAFT as of JULY 15, 2023 For Public Comment @ AAIC23

1 NIA-AA Revised Clinical Criteria for Alzheimer's Disease

31 Defining neurodegenerative diseases biologically, rather than based on syndromic

55 1.1) Modular updates

63 1.2) Motivation for the modules that are updated

87 Categorization of biomarkers as defined here refers to grouping biomarkers into

395 3.3.3) Clinical context

421 4) Biological disease staging

605 5) Clinical staging

606 5.1) Numeric clinical staging

672 6) Integrated biological and clinical staging

700 7) Multi-modal biomarker profiles and identification of comorbid pathologic change

701 We distinguish multi-modal biomarker “profiles” from AD biological staging. Biomarker

756 8) Treatment effects

760 disease targeted therapies promises to be transformative. Anti Aβ immunotherapy can

800 9) Diversity and need for more representative cohorts

817 10) Future Directions

993 62. Li S, Naganawa M, Pracitto R, et al. Assessment of test-retest reproducibility of [(18)F]SynVesT-

You might also like